

Ddddd

1-69,69-293,293-318,318-498,498-960

1. Benyamina, A. & Reynaud, M. [Therapeutic use of cannabis derivatives]. *Rev Prat* **64**, 165-168 (2014).
2. Qin, H. & Ruan, Z. H. The Role of Monoacylglycerol Lipase (MAGL) in the Cancer Progress. *Cell Biochem Biophys* (2014).
3. Cipriano, M., Gouveia-Figueira, S., Persson, E., Nording, M. & Fowler, C. J. The influence of monoacylglycerol lipase inhibition upon the expression of epidermal growth factor receptor in human PC-3 prostate cancer cells. *BMC Res Notes* **7**, 441 (2014).
4. Morelli, M. B. et al. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2. *Int J Cancer* **134**, 2534-2546 (2014).
5. Murase, R. et al. Targeting multiple cannabinoid antitumor pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. *Br J Pharmacol* (2014).
6. Moreno, E. et al. Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling. *J Biol Chem* (2014).
7. Georgakilas, A. G. et al. Systemic DNA damage accumulation under in vivo tumor growth can be inhibited by the antioxidant Tempol. *Cancer Lett* **353**, 248-257 (2014).
8. Rocha, F. C., Dos Santos Junior, J. G., Stefano, S. C. & da Silveira, D. X. Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas. *J Neurooncol* **116**, 11-24 (2014).
9. Hermanson, D. J., Gamble-George, J. C., Marnett, L. J. & Patel, S. Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. *Trends Pharmacol Sci* (2014).
10. Moreno-Sanz, G. et al. Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain. *Pharmacol Res* **87C**, 87-93 (2014).
11. Dong, W. et al. Simulation of Swanson's Literature-Based Discovery: Anandamide Treatment Inhibits Growth of Gastric Cancer Cells In Vitro and In Silico. *PLoS One* **9**, e100436 (2014).
12. Nader, J. et al. Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB receptors. *Neuropharmacology* (2014).
13. Haggstrom, J. et al. Potential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: A Bayesian network analysis of data from a tissue microarray. *Prostate* **74**, 1107-1117 (2014).
14. Giordano, D., Draves, K. E., Li, C., Hohl, T. M. & Clark, E. A. Nitric Oxide Regulates BAFF Expression and T Cell-Independent Antibody Responses. *J Immunol* (2014).
15. Rahman, I. A., Tsuboi, K., Uyama, T. & Ueda, N. New players in the fatty acyl ethanolamide metabolism. *Pharmacol Res* (2014).
16. Hu, W. R. et al. Monoacylglycerol lipase promotes metastases in nasopharyngeal

- carcinoma. *Int J Clin Exp Pathol* **7**, 3704-3713 (2014).
17. Bjorklund, E., Larsson, T. N., Jacobsson, S. O. & Fowler, C. J. Ketoconazole Inhibits the Cellular Uptake of Anandamide via Inhibition of FAAH at Pharmacologically Relevant Concentrations. *PLoS One* **9**, e87542 (2014).
 18. Bar-Sela, G., Avisar, A., Batash, R. & Schaffer, M. Is the clinical use of cannabis by oncology patients advisable? *Curr Med Chem* **21**, 1923-1930 (2014).
 19. Bjorklund, E., Blomqvist, A., Hedlin, J., Persson, E. & Fowler, C. J. Involvement of Fatty Acid amide hydrolase and Fatty Acid binding protein 5 in the uptake of anandamide by cell lines with different levels of Fatty Acid amide hydrolase expression: a pharmacological study. *PLoS One* **9**, e103479 (2014).
 20. Bakali, E. et al. Human urothelial cell lines as potential models for studying cannabinoid and excitatory receptor interactions in the urinary bladder. *Naunyn Schmiedebergs Arch Pharmacol* (2014).
 21. Ravi, J., Sneh, A., Shilo, K., Nasser, M. W. & Ganju, R. K. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. *Oncotarget* (2014).
 22. Afzal, O. et al. Docking based virtual screening and molecular dynamics study to identify potential monoacylglycerol lipase inhibitors. *Bioorg Med Chem Lett* (2014).
 23. Kohnz, R. A. & Nomura, D. K. Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. *Chem Soc Rev* (2014).
 24. Bluett, R. J. et al. Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. *Transl Psychiatry* **4**, e408 (2014).
 25. Yang, L. et al. Celastrol attenuates inflammatory and neuropathic pain mediated by cannabinoid receptor type 2. *Int J Mol Sci* **15**, 13637-13648 (2014).
 26. Hasko, J. et al. CB2 Receptor Activation Inhibits Melanoma Cell Transmigration through the Blood-Brain Barrier. *Int J Mol Sci* **15**, 8063-8074 (2014).
 27. Ramer, R., Fischer, S., Haustein, M., Manda, K. & Hinz, B. CANNABINOIDS INHIBIT angiogenic capacities of Endothelial cells via release of Tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells. *Biochem Pharmacol* (2014).
 28. Haustein, M., Ramer, R., Linnebacher, M., Manda, K. & Hinz, B. CANNABINOIDS INCREASE LUNG CANCER CELL LYSIS BY LYMPHOKINE-ACTIVATED KILLER CELLS VIA UPREGULATION OF ICAM-1. *Biochem Pharmacol* (2014).
 29. Davis, M. P. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. *Expert Opin Investig Drugs* 1-18 (2014).
 30. Chakravarti, B., Ravi, J. & Ganju, R. K. Cannabinoids as therapeutic agents in cancer: current status and future implications. *Oncotarget* (2014).
 31. Messalli, E. M., Grauso, F., Luise, R., Angelini, A. & Rossiello, R. Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors. *Am J Obstet Gynecol* (2014).
 32. Fukuda, S. et al. Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. *BMC Musculoskelet Disord* **15**, 275 (2014).
 33. Park, S. W. et al. Anticancer effects of anandamide on head and neck squamous cell carcinoma cells via the production of receptor-independent reactive oxygen species.

Head Neck (2014).

34. Picardi, P., Ciaglia, E., Proto, M. & Pisanti, S. Anandamide inhibits breast tumor-induced angiogenesis. *Transl Med UniSa* **10**, 8-12 (2014).
35. Sousa-Valente, J., Varga, A., Ananthan, K., Khajuria, A. & Nagy, I. Anandamide in primary sensory neurons: too much of a good thing? *Eur J Neurosci* **39**, 409-418 (2014).
36. Gomez, R. et al. Anandamide impairs cell growth and induces apoptosis in chondrocytes. *J Orthop Res* (2014).
37. Masoodi, M. et al. A role for oleoylethanolamide in chronic lymphocytic leukemia. *Leukemia* (2014).
38. Pacher, P. Towards the use of non-psychoactive cannabinoids for prostate cancer. *Br J Pharmacol* **168**, 76-78 (2013).
39. Robson, P. J. Therapeutic potential of cannabinoid medicines. *Drug Test Anal* (2013).
40. Hazekamp, A. & Heerdink, E. R. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. *Eur J Clin Pharmacol* (2013).
41. Pisanti, S., Picardi, P., D'Alessandro, A., Laezza, C. & Bifulco, M. The endocannabinoid signaling system in cancer. *Trends Pharmacol Sci* (2013).
42. Karasu, T. et al. The Effect of Mifepristone (RU486) on the Endocannabinoid System in Human Plasma and First Trimester Trophoblast of Women undergoing Termination of Pregnancy. *J Clin Endocrinol Metab* jc20132922 (2013).
43. Sharkey, K. A., Darmani, N. A. & Parker, L. A. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. *Eur J Pharmacol* (2013).
44. Zhang, L. P., Ma, F., Abshire, S. M. & Westlund, K. N. Prolonged High Fat / Alcohol Exposure Increases TRPV4 and Its Functional Responses in Pancreatic Stellate Cells. *Am J Physiol Regul Integr Comp Physiol* (2013).
45. Matos, I., Bento, A. F., Marcon, R., Claudino, R. F. & Calixto, J. B. Preventive and therapeutic oral administration of the pentacyclic triterpene alpha,beta-amyrin ameliorates dextran sulfate sodium-induced colitis in mice: The relevance of cannabinoid system. *Mol Immunol* **54**, 482-492 (2013).
46. Cheng, J. et al. Potential role of CYP2D6 in the central nervous system. *Xenobiotica* (2013).
47. Pezuk, J. A. et al. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. *Cancer Gene Ther* **20**, 499-506 (2013).
48. Gebeh, A. K., Willets, J. M., Marczylo, T. H. & Konje, J. C. Plasma Anandamide and Related N-acylethanolamide Levels are not Elevated in Pregnancies Complicated by Hyperemesis Gravidarum. *J Matern Fetal Neonatal Med* (2013).
49. Aaltonen, N. et al. Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase. *Chem Biol* **20**, 379-390 (2013).
50. Tanasescu, R. & Constantinescu, C. S. Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. *Expert Opin Drug Metab Toxicol* (2013).
51. Chew, S. C. et al. Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRalpha and HNF4alpha) on docetaxel disposition in Chinese nasopharyngeal cancer patients. *Eur J Clin Pharmacol* (2013).
52. Gangemi, G. et al. PBOX-15 induces apoptosis and improves the efficacy of

- oxaliplatin in human colorectal cancer cell lines. *Eur J Pharmacol* **714**, 379-387 (2013).
53. Keimpema, E. et al. Nerve growth factor scales endocannabinoid signaling by regulating monoacylglycerol lipase turnover in developing cholinergic neurons. *Proc Natl Acad Sci U S A* (2013).
 54. Lang, U. E. & Borgwardt, S. Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies. *Cell Physiol Biochem* **31**, 761-777 (2013).
 55. Kapoor, S. Modulation of intracellular pathways by anandamide and its evolving role in oncology. *Eur J Cancer* (2013).
 56. Ueda, N., Tsuboi, K. & Uyama, T. Metabolism of endocannabinoids and related N-acylethanolamines: Canonical and alternative pathways. *FEBS J* (2013).
 57. Callaghan, R. C., Allebeck, P. & Sidorchuk, A. Marijuana use and risk of lung cancer: a 40-year cohort study. *Cancer Causes Control* **24**, 1811-1820 (2013).
 58. Hernan Perez de la Ossa, D. et al. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. *PLoS One* **8**, e54795 (2013).
 59. Uyama, T. et al. Involvement of phospholipase A/acyltransferase-1 in N-acylphosphatidylethanolamine generation. *Biochim Biophys Acta* (2013).
 60. De Chiara, V. et al. Interleukin-1beta alters the sensitivity of cannabinoid CB1 receptors controlling glutamate transmission in the striatum. *Neuroscience* **250**, 232-239 (2013).
 61. Li, H. et al. Inhibition Of Fatty Acid Amide Hydrolase Activates Nrf2 Signaling And Induces Heme Oxygenase 1 Transcription In Breast Cancer Cells. *Br J Pharmacol* (2013).
 62. Romano, B. et al. Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol. *Phytomedicine* (2013).
 63. Bilmin, K., Kopczynska, B. & Grieb, P. Influence of serum and albumin on the in vitro anandamide cytotoxicity toward C6 glioma cells assessed by the MTT cell viability assay: implications for the methodology of the MTT tests. *Folia Neuropathol* **51**, 44-50 (2013).
 64. Khasabova, I. A. et al. Increased Anandamide Uptake by Sensory Neurons Contributes to Hyperalgesia in a Model of Cancer Pain. *Neurobiol Dis* (2013).
 65. Kotsikorou, E. et al. Identification of the GPR55 Antagonist Binding Site Using a Novel Set of High Potency GPR55 Selective Ligands. *Biochemistry* (2013).
 66. Khan, K. A. et al. HIV-1 Nef Interacts with HCV Core, Recruits TRAF2, TRAF5 and TRAF6, and Stimulates HIV-1 Replication in Macrophages. *J Innate Immun* (2013).
 67. Shubbar, E. et al. High levels of gamma-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer. *BMC Cancer* **13**, 47 (2013).
 68. Wu, C. S. et al. GPR55, a G-Protein Coupled Receptor for Lysophosphatidylinositol, Plays a Role in Motor Coordination. *PLoS One* **8**, e60314 (2013).
 69. Gebeh, A. K. et al. Elevated Anandamide and Related N-Acylethanolamine Levels Occur in the Peripheral Blood of Women With Ectopic Pregnancy and Are Mirrored by Changes in Peripheral Fatty Acid Amide Hydrolase Activity. *J Clin*

Endocrinol Metab (2013).

70. Tashkin, D. P. Effects of marijuana smoking on the lung. *Ann Am Thorac Soc* **10**, 239-247 (2013).
71. Gustafsson, S. B. et al. Effects of cannabinoids and related fatty acids upon the viability of P19 embryonal carcinoma cells. *Arch Toxicol* (2013).
72. Rimmerman, N. et al. Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death. *Cell Death Dis* **4**, e949 (2013).
73. Repossi, G., Pasqualini, M. E., Das, U. N. & Eynard, A. R. Differential Modulation of Tumor Cell Proliferation and their Endocannabinoid System by Polyunsaturated Fatty Acids. *Curr Pharm Des* (2013).
74. Hecht, M. et al. Cytotoxic effect of Efavirenz is selective against cancer cells and associated with the cannabinoid system. *AIDS* (2013).
75. Paul, A. G., Chandran, B. & Sharma-Walia, N. Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies. *Transl Res* **162**, 77-92 (2013).
76. Cazade, M. et al. Cross Modulation and Molecular Interaction at the Cav3.3 Protein between the Endogenous Lipids and the T-type Calcium Channel Antagonist TTA-A2. *Mol Pharmacol* (2013).
77. Cridge, B. J. & Rosengren, R. J. Critical appraisal of the potential use of cannabinoids in cancer management. *Cancer Manag Res* **5**, 301-313 (2013).
78. El Amrani, L. et al. CHANGES ON METABOLIC PARAMETERS INDUCED BY ACUTE CANNABINOID ADMINISTRATION (CBD, THC) IN A RAT EXPERIMENTAL MODEL OF NUTRITIONAL VITAMIN A DEFICIENCY. *Nutr Hosp* **28**, 857-867 (2013).
79. Prather, P. L. et al. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. *Biochem Biophys Res Commun* **441**, 339-343 (2013).
80. Hazekamp, A. & Romano, A. Cannabis Oil: chemical evaluation of an upcoming cannabis-based medicine. *Cannabinoids* **1**, 1-11 (2013).
81. Naftali, T. et al. Cannabis Induces a Clinical Response in Patients with Crohn's Disease: a Prospective Placebo-Controlled Study. *Clin Gastroenterol Hepatol* (2013).
82. Behrend, S. W. Cannabinoids may be therapeutic in breast cancer. *Oncol Nurs Forum* **40**, 191-192 (2013).
83. Ellert-Miklaszewska, A., Ciechomska, I. & Kaminska, B. Cannabinoid signaling in glioma cells. *Adv Exp Med Biol* **986**, 209-220 (2013).
84. Duff, G. et al. Cannabinoid Receptor CB2 Modulates Axon Guidance. *PLoS One* **8**, e70849 (2013).
85. Solinas, M. et al. Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect. *PLoS One* **8**, e76918 (2013).
86. Ward, S. J., McAllister, S. D., Neelakantan, H. & Walker, E. A. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy. *Br J Pharmacol* (2013).

87. Feinshtein, V. et al. Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study. *Am J Obstet Gynecol* (2013).
88. Feinshtein, V. et al. Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines. *PeerJ* **1**, e153 (2013).
89. Rempel, V. et al. Antagonists for the orphan G protein-coupled receptor GPR55 based on a coumarin scaffold. *J Med Chem* (2013).
90. Varga, A. et al. Anandamide produced by Ca-insensitive enzymes induces excitation in primary sensory neurons. *Pflugers Arch* (2013).
91. Amoako, A. A. et al. Anandamide modulates human sperm motility: implications for men with asthenozoospermia and oligoasthenoteratozoospermia. *Hum Reprod* (2013).
92. Laezza, C., d'Alessandro, A., Malfitano, A. M. & Bifulco, M. Anandamide inhibits the Wnt/beta-catenin signalling pathway in human breast cancer MDA MB 231 cells. *Eur J Cancer* **49(8)**, 2066-2067 (2013).
93. Fowler, C. J. et al. Tumour epithelial expression levels of endocannabinoid markers modulates the value of endoglin-positive vascular density as a prognostic marker in prostate cancer. *Biochim Biophys Acta* (2012).
94. Mulvihill, M. M. & Nomura, D. K. Therapeutic Potential of Monoacylglycerol Lipase Inhibitors. *Life Sci* (2012).
95. Idris, A. I. The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease. *Bonekey Rep* **1**, 224 (2012).
96. Murphy, N. et al. The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation. *J Neuroinflammation* **9**, 79 (2012).
97. Gamage, T. F. & Lichtman, A. H. The endocannabinoid system: role in energy regulation. *Pediatr Blood Cancer* **58**, 144-148 (2012).
98. Hamtiaux, L. et al. The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action. *BMC Cancer* **12**, 92 (2012).
99. Pertwee, R. G. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. *Philos Trans R Soc Lond B Biol Sci* **367**, 3353-3363 (2012).
100. Pellei, M. et al. Synthesis and Biological Activity of Ester- and Amide-Functionalized Imidazolium Salts and Related Water-Soluble Coinage Metal N-Heterocyclic Carbene Complexes. *Inorg Chem* (2012).
101. Windsor, M. A. et al. Substrate-Selective Inhibition of Cyclooxygenase-2: Development and Evaluation of Achiral Profen Probes. *ACS Med Chem Lett* **3**, 759-763 (2012).
102. Zhou, L. et al. Serum Metabolic Profiling Study of Hepatocellular Carcinoma Infected with Hepatitis B or Hepatitis C Virus by Using Liquid Chromatography-Mass Spectrometry. *J Proteome Res* (2012).
103. Grimaldi, C. & Capasso, A. Role of Lipid Rafts/Caveolae in the Anticancer Effect of Endocannabinoids. *Mini Rev Med Chem* (2012).
104. Idris, A. I. & Ralston, S. H. Role of cannabinoids in the regulation of bone remodeling. *Front Endocrinol (Lausanne)* **3**, 136 (2012).

105. Van Dross, R., Soliman, E., Jha, S., Johnson, T. & Mukhopadhyay, S. Receptor-dependent and Receptor-independent Endocannabinoid Signaling: A Therapeutic Target for Regulation of Cancer Growth. *Life Sci* (2012).
106. Manera, C. et al. Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold. *Eur J Med Chem* **52**, 284-294 (2012).
107. Lacson, J. C. et al. Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. *Cancer* (2012).
108. Hernan Perez de la Ossa, D. et al. Poly-epsilon-caprolactone microspheres as a drug delivery system for cannabinoid administration: Development, characterization and in vitro evaluation of their antitumoral efficacy. *J Control Release* **161**, 927-932 (2012).
109. Klumpers, L. E. et al. Novel Delta(9) -tetrahydrocannabinol formulation Namisol(R) has beneficial pharmacokinetics and promising pharmacodynamic effects. *Br J Clin Pharmacol* **74**, 42-53 (2012).
110. Vargas-Inchaustegui, D. A., Xiao, P., Tuero, I., Patterson, L. J. & Robert-Guroff, M. NK and CD4+ T cell cooperative immune responses correlate with control of disease in a macaque simian immunodeficiency virus infection model. *J Immunol* **189**, 1878-1885 (2012).
111. Fowler, D. W., Copier, J., Wilson, N., Dalgleish, A. G. & Bodman-Smith, M. D. Mycobacteria activate gammadelta T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. *Cancer Immunol Immunother* **61**, 535-547 (2012).
112. Fowler, C. J. Monoacylglycerol lipase-a target for drug development? *Br J Pharmacol* (2012).
113. Zhang, B. et al. Mitochondria Distinguish Granule-Stored from de novo Synthesized Tumor Necrosis Factor Secretion in Human Mast Cells. *Int Arch Allergy Immunol* **159**, 23-32 (2012).
114. Rubinsztein, D. C., Shpilka, T. & Elazar, Z. Mechanisms of autophagosome biogenesis. *Curr Biol* **22**, R29-R34 (2012).
115. Stanley, C. P., Hind, W. H. & O'Sullivan, S. E. Is the cardiovascular system a therapeutic target for CBD? *Br J Clin Pharmacol* (2012).
116. Wilkerson, J. L. et al. Intrathecal cannabidiol CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels. *Pain* (2012).
117. Amoako, A. A. et al. Impact of reference gene selection for type 2 cannabinoid receptor gene expression studies in human spermatozoa. *Andrologia* (2012).
118. Zhao, P. & Abood, M. E. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. *Life Sci* (2012).
119. Uyama, T. et al. Generation of N-Acylphosphatidylethanolamine by Members of the Phospholipase A/Acyltransferase (PLA/AT) Family. *J Biol Chem* (2012).
120. Lenglet, S. et al. Fatty Acid Amide Hydrolase Deficiency Enhances Intraplaque Neutrophil Recruitment in Atherosclerotic Mice. *Arterioscler Thromb Vasc Biol* (2012).
121. Peterfi, Z. et al. Endocannabinoid-mediated long-term depression of afferent excitatory synapses in hippocampal pyramidal cells and GABAergic interneurons. *J*

- Neurosci* **32**, 14448-14463 (2012).
122. Rani Sagar, D., Burston, J. J., Woodhams, S. G. & Chapman, V. Dynamic changes to the endocannabinoid system in models of chronic pain. *Philos Trans R Soc Lond B Biol Sci* **367**, 3300-3311 (2012).
 123. Hsu, K. L. et al. DAGLbeta inhibition perturbs a lipid network involved in macrophage inflammatory responses. *Nat Chem Biol* (2012).
 124. Killian, P. H. et al. Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. *Carcinogenesis* **33**, 2507-2519 (2012).
 125. Engeli, S. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. *Handb Exp Pharmacol* **209**, 357-381 (2012).
 126. Arnold, J. C., Hone, P., Holland, M. L. & Allen, J. D. CB(2) and TRPV(1) receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells. *Pharmacol Rep* **64**, 751-757 (2012).
 127. Sagredo, O., Pazos, M. R., Valdeolivas, S. & Fernandez-Ruiz, J. Cannabinoids: novel medicines for the treatment of Huntington's disease. *Recent Pat CNS Drug Discov* **7**, 41-48 (2012).
 128. Echigo, R., Sugimoto, N., Yachie, A. & Ohno-Shosaku, T. Cannabinoids inhibit peptidoglycan-induced phosphorylation of NF-kappaB and cell growth in U87MG human malignant glioma cells. *Oncol Rep* (2012).
 129. Brown, I. et al. Cannabinoids and Omega-3/6 Endocannabinoids as Cell Death and Anticancer Modulators. *Prog Lipid Res* (2012).
 130. Khasabova, I. A. et al. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. *J Neurosci* **32**, 7091-7101 (2012).
 131. Rajesh, M. et al. Cannabinoid 1 Receptor Promotes Cardiac Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in Diabetic Cardiomyopathy. *Diabetes* (2012).
 132. Takeda, S. et al. Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. *Toxicol Lett* (2012).
 133. Ramer, R. et al. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. *FASEB J* **26**, 1535-1548 (2012).
 134. Solinas, M. et al. CANNABIDIOL INHIBITS ANGIOGENESIS BY MULTIPLE MECHANISMS. *Br J Pharmacol* (2012).
 135. Zhornitsky, S. & Potvin, S. Cannabidiol in Humans-The Quest for Therapeutic Targets. *Pharmaceuticals (Basel)* **5**, 529-552 (2012).
 136. Massi, P., Solinas, M., Cinquina, V. & Parolaro, D. CANNABIDIOL AS POTENTIAL ANTICANCER DRUG. *Br J Clin Pharmacol* (2012).
 137. Karmaus, P. W., Wagner, J. G., Harkema, J. R., Kaminski, N. E. & Kaplan, B. L. Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice. *J Immunotoxicol* (2012).
 138. Liu, X. et al. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. *Mol Cancer Ther* **11**, 1421-1431 (2012).
 139. Vidinsky, B. et al. Anti-proliferative and anti-angiogenic effects of CB2R agonist (JWH-133) in non-small lung cancer cells (A549) and human umbilical vein endothelial cells: an in vitro investigation. *Folia Biol (Praha)* **58**, 75-80 (2012).
 140. Li, K. et al. Anti-Inflammatory Role of Cannabidiol and O-1602 in Cerulein-

- Induced Acute Pancreatitis in Mice. *Pancreas* (2012).
141. Rettori, E., De Laurentiis, A., Zorrilla Zubilete, M., Rettori, V. & Elverdin, J. C. Anti-Inflammatory Effect of the Endocannabinoid Anandamide in Experimental Periodontitis and Stress in the Rat. *Neuroimmunomodulation* **19**, 293-303 (2012).
 142. Laezza, C. et al. Anandamide inhibits the Wnt/beta-catenin signalling pathway in human breast cancer MDA MB 231 cells. *Eur J Cancer* (2012).
 143. Johnson, J. R., Lossignol, D., Burnell-Nugent, M. & Fallon, M. T. An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics. *J Pain Symptom Manage* (2012).
 144. Schicho, R. & Storr, M. A potential role for GPR55 in gastrointestinal functions. *Curr Opin Pharmacol* (2012).
 145. Kreisl, T. N. et al. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. *Neuro Oncol* (2012).
 146. Simpson, C. D. et al. A genome wide shRNA screen identifies alpha/beta hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance. *Apoptosis* (2012).
 147. Liao, Y. S., Wu, J., Wang, P. & Zhang, H. [Anandamide inhibits the growth of colorectal cancer cells through CB1 and lipid rafts.]. *Zhonghua Zhong Liu Za Zhi* **33**, 256-259 (2011).
 148. Malfitano, A. M. et al. Update on the endocannabinoid system as an anticancer target. *Expert Opin Ther Targets* **15**, 297-308 (2011).
 149. Garami, A. et al. Thermoregulatory phenotype of the trpv1 knockout mouse: thermoeffector dysbalance with hyperkinesia. *J Neurosci* **31**, 1721-1733 (2011).
 150. Karasu, T., Marczylo, T. H., Maccarrone, M. & Konje, J. C. The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility. *Hum Reprod Update* (2011).
 151. Wasik, A. M., Christensson, B. & Sander, B. The role of cannabinoid receptors and the endocannabinoid system in mantle cell lymphoma and other non-Hodgkin lymphomas. *Semin Cancer Biol* (2011).
 152. Hu, G., Ren, G. & Shi, Y. The putative cannabinoid receptor GPR55 promotes cancer cell proliferation. *Oncogene* **30**, 139-141 (2011).
 153. Bowles, D. W., O'Bryant, C. L., Camidge, D. R. & Jimeno, A. The intersection between cannabis and cancer in the United States. *Crit Rev Oncol Hematol* (2011).
 154. Steiner, A. A. et al. The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors. *J Physiol* (2011).
 155. Di Sabatino, A. et al. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. *Mucosal Immunol* (2011).
 156. Horvath, B., Mukhopadhyay, P., Hasko, G. & Pacher, P. The Endocannabinoid System: Plant-Derived Cannabinoids in Diabetes and Diabetic Complications. *Am J Pathol* (2011).
 157. Grimaldi, C. & Capasso, A. The Endocannabinoid System in the Cancer Therapy: An Overview. *Curr Med Chem* (2011).
 158. Diaz-Laviada, I. The endocannabinoid system in prostate cancer. *Nat Rev Urol*

- (2011).
159. Guindon, J. & Hohmann, A. G. The endocannabinoid system and cancer: Therapeutic Implications. *Br J Pharmacol* (2011).
 160. Moreno-Sanz, G. et al. The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system. *Pharmacol Res* (2011).
 161. Russo, E. B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol* **163**, 1344-1364 (2011).
 162. Lorente, M. et al. Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action. *Cell Death Differ* (2011).
 163. Foroughi, M., Hendson, G., Sargent, M. A. & Steinbok, P. Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas-possible role of Cannabis inhalation. *Childs Nerv Syst* **27**, 671-679 (2011).
 164. Zoppi, S. et al. Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation. *Neuropsychopharmacology* **36**, 805-818 (2011).
 165. Ren, Y., Xu, Y. J. & Tan, Z. M. Possible involvement of the endocannabinoid system in memory modulation effect of general anesthetics. *Med Hypotheses* (2011).
 166. Marshall, A. D., Lagutina, I. & Grosveld, G. C. PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis. *Cancer Res* **71**, 7471-7480 (2011).
 167. Ali, A. M., Greenberg, D., Wishart, G. C. & Pharoah, P. Patient and tumour characteristics, management, and age-specific survival in women with breast cancer in the East of England. *Br J Cancer* **104**, 564-570 (2011).
 168. Brown, I. et al. Omega-3 N-acyl ethanolamines are endogenously synthesised from omega-3 fatty acids in different human prostate and breast cancer cell lines. *Prostaglandins Leukot Essent Fatty Acids* (2011).
 169. Thapa, D. et al. Novel hexahydrocannabinol analogs as potential anti-cancer agents inhibit cell proliferation and tumor angiogenesis. *Eur J Pharmacol* **650**, 64-71 (2011).
 170. Nomura, D. K. et al. Monoacylglycerol Lipase Exerts Dual Control over Endocannabinoid and Fatty Acid Pathways to Support Prostate Cancer. *Chem Biol* **18**, 846-856 (2011).
 171. Ye, L. et al. Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. *Cancer Lett* (2011).
 172. Clark, P. A., Capuzzi, K. & Fick, C. Medical marijuana: Medical necessity versus political agenda. *Med Sci Monit* **17**, RA249-RA261 (2011).
 173. Trabert, B., Sigurdson, A. J., Sweeney, A. M., Strom, S. S. & McGlynn, K. A. Marijuana use and testicular germ cell tumors. *Cancer* **117**, 848-853 (2011).
 174. Proto, M. C. et al. Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth. *J Cell Physiol* (2011).
 175. Sreevalsan, S., Joseph, S., Jutooru, I., Chadalapaka, G. & Safe, S. H. Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent. *Anticancer Res* **31**, 3799-3807 (2011).
 176. Hamtiaux, L. et al. Increasing Antiproliferative Properties of Endocannabinoids in N1E-115 Neuroblastoma Cells through Inhibition of Their Metabolism. *PLoS One* **6**, e26823 (2011).

177. Khasabova, I. A., Chandiramani, A., Harding-Rose, C., Simone, D. A. & Seybold, V. S. Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. *Pharmacol Res* (2011).
178. Lou, Z. Y., Zhao, C. B. & Xiao, B. G. Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist. *J Neurosci Res* (2011).
179. Mukhopadhyay, P. et al. Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. *Free Radic Biol Med* **50**, 179-195 (2011).
180. Ruhaak, L. R. et al. Evaluation of the Cyclooxygenase Inhibiting Effects of Six Major Cannabinoids Isolated from *Cannabis sativa*. *Biol Pharm Bull* **34**, 774-778 (2011).
181. De Petrocellis, L. et al. Effects of cannabinoids and cannabinoid-enriched *Cannabis* extracts on TRP channels and endocannabinoid metabolic enzymes. *Br J Pharmacol* **163**, 1479-1494 (2011).
182. Matuszak, N. et al. Dual inhibition of MAGL and type II topoisomerase by N-phenylmaleimides as a potential strategy to reduce neuroblastoma cell growth. *Eur J Pharm Sci* (2011).
183. Purohit, V., Rapaka, R. & Shurtleff, D. Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia. *Mol Neurobiol* **44**, 102-110 (2011).
184. Filipeanu, C. M., Guidry, J. J., Leonard, S. T. & Winsauer, P. J. Delta9-THC increases endogenous AHA1 expression in rat cerebellum and may modulate CB1 receptor function during chronic use. *J Neurochem* **118**, 1101-1112 (2011).
185. Brisbois, T. D. et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. *Ann Oncol* (2011).
186. Argaw, A. et al. Concerted Action of CB1 Cannabinoid Receptor and Deleted in Colorectal Cancer in Axon Guidance. *J Neurosci* **31**, 1489-1499 (2011).
187. Ware, M. A. Clearing the smoke around medical marijuana. *Clin Pharmacol Ther* **90**, 769-771 (2011).
188. Brighton, P. J., Marczyklo, T. H., Rana, S., Konje, J. C. & Willets, J. M. Characterising the endocannabinoid system, CB1 receptor signalling and desensitization in human myometrium. *Br J Pharmacol* (2011).
189. Khasabova, I. A. et al. CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain. *Behav Pharmacol* **22**, 607-616 (2011).
190. Hermanson, D. J. & Marnett, L. J. Cannabinoids, endocannabinoids, and cancer. *Cancer Metastasis Rev* (2011).
191. Wilner, L. S. & Arnold, R. M. Cannabinoids in the treatment of symptoms in cancer and AIDS, 2nd edition #93. *J Palliat Med* **14**, 509-510 (2011).
192. Saghafi, N., Lam, D. K. & Schmidt, B. L. Cannabinoids attenuate cancer pain and proliferation in a mouse model. *Neurosci Lett* **488**, 247-251 (2011).
193. Preet, A. et al. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. *Cancer Prev Res (Phila)* **4**, 65-75 (2011).
194. Ruiz-Valdepenas, L. et al. Cannabidiol reduces lipopolysaccharide-induced

- vascular changes and inflammation in the mouse brain: an intravital microscopy study. *J Neuroinflammation* **8**, 5 (2011).
195. Shrivastava, A., Kuzontkoski, P. M., Groopman, J. E. & Prasad, A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. *Mol Cancer Ther* **10**, 1161-1172 (2011).
 196. Kuc, C., Jenkins, A. & Van Dross, R. T. Arachidonoyl ethanolamide (AEA)-induced apoptosis is mediated by J-series prostaglandins and is enhanced by fatty acid amide hydrolase (FAAH) blockade. *Mol Carcinog* (2011).
 197. Park, J. M. et al. Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells. *J Cell Biochem* (2011).
 198. Nithipatikom, K., Isbell, M. A., Endsley, M. P., Woodliff, J. E. & Campbell, W. B. Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. *Prostaglandins Other Lipid Mediat* **94**, 34-43 (2011).
 199. Perwitasari, D. A. et al. Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. *Int J Clin Pharm* **33**, 33-43 (2011).
 200. Wu, X. et al. Alteration of endocannabinoid system in human gliomas. *J Neurochem* (2011).
 201. Listed, N. A. Adverse effects of cannabis. *Prescrire Int* **20**, 18-23 (2011).
 202. Torres, S. et al. A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma. *Mol Cancer Ther* **10**, 90-103 (2011).
 203. Wu, W. J. et al. [Membrane cholesterol mediates the endocannabinoids-anandamide effect on HepG2 cells.]. *Zhonghua Gan Zang Bing Za Zhi* **18**, 204-208 (2010).
 204. Peat, S. Using cannabinoids in pain and palliative care. *Int J Palliat Nurs* **16**, 481-485 (2010).
 205. Fowler, C. J., Hammarsten, P. & Bergh, A. Tumour Cannabinoid CB(1) Receptor and Phosphorylated Epidermal Growth Factor Receptor Expression Are Additive Prognostic Markers for Prostate Cancer. *PLoS One* **5**, e15205 (2010).
 206. Yamada, T. et al. TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer. *Urology* **76**, 509.e1-509.e7 (2010).
 207. Tazi, E. & Errihani, H. Treatment of cachexia in oncology. *Indian J Palliat Care* **16**, 129-137 (2010).
 208. Mukhopadhyay, B. et al. Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor- $\{\gamma\}$. *J Biol Chem* (2010).
 209. Lin, H. C. et al. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension. *J Hepatol* (2010).
 210. Nallendran, V. et al. The plasma levels of the endocannabinoid, anandamide, increase with the induction of labour. *BJOG* (2010).
 211. Guida, M. et al. The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma. *Endocrinology* **151**, 921-928 (2010).
 212. De Laurentiis, A. et al. The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor-alpha induced by lipopolysaccharide. *J Neuroimmunol* (2010).
 213. Nunez, M., Perdomo, S., Moreta, J., Santos-Briz, A. & Gonzalez-Sarmiento, R. The

- G1359A-CNR1 gene polymorphism is associated to glioma in Spanish patients. *Clin Transl Oncol* **12**, 825-828 (2010).
214. Santha, P., Jenes, A., Somogyi, C. & Nagy, I. The endogenous cannabinoid anandamide inhibits transient receptor potential vanilloid type 1 receptor-mediated currents in rat cultured primary sensory neurons. *Acta Physiol Hung* **97**, 149-158 (2010).
 215. Fowler, C. J. et al. Targeting the Endocannabinoid System for the Treatment of Cancer - A Practical View. *Curr Top Med Chem* (2010).
 216. Gao, M., Wang, M., Miller, K. D., Hutchins, G. D. & Zheng, Q. H. Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging. *Bioorg Med Chem* (2010).
 217. Lam, P. M., Marczylo, T. H. & Konje, J. C. Simultaneous measurement of three N-acyl ethanolamides in human bio-matrices using ultra performance liquid chromatography-tandem mass spectrometry. *Anal Bioanal Chem* (2010).
 218. Gallotta, D. et al. Rimonabant-induced apoptosis in leukemia cell lines: activation of caspase-dependent and -independent pathways. *Biochem Pharmacol* (2010).
 219. Miranville, A., Herling, A. W., Biemer-Daub, G. & Voss, M. D. Reversal of Inflammation-Induced Impairment of Glucose Uptake in Adipocytes by Direct Effect of CB1 Antagonism on Adipose Tissue Macrophages. *Obesity (Silver Spring)* (2010).
 220. Kawamata, T., Niiyama, Y., Yamamoto, J. & Furuse, S. Reduction of bone cancer pain by CB1 activation and TRPV1 inhibition. *J Anesth* (2010).
 221. Amoako, A. A. et al. Quantitative analysis of anandamide and related acylethanolamides in human seminal plasma by ultra performance liquid chromatography tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* (2010).
 222. Duran, M. et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. *Br J Clin Pharmacol* **70**, 656-663 (2010).
 223. Karschner, E. L., Darwin, W. D., Goodwin, R. S., Wright, S. & Huestis, M. A. Plasma Cannabinoid Pharmacokinetics following Controlled Oral {Delta}9-Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration. *Clin Chem* (2010).
 224. McAllister, S. D. et al. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. *Breast Cancer Res Treat* (2010).
 225. Fernandez-Solari, J., Prestifilippo, J. P., Ossola, C. A., Rettori, V. & Elverdin, J. C. Participation of the endocannabinoid system in lipopolysaccharide-induced inhibition of salivary secretion. *Arch Oral Biol* (2010).
 226. Jesus, M. L. et al. Opposite changes in cannabinoid CB(1) and CB(2) receptor expression in human gliomas. *Neurochem Int* (2010).
 227. Frampton, G., Coufal, M., Li, H., Ramirez, J. & Demorrow, S. Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling. *Exp Cell Res* (2010).
 228. Fonseca, B. M. et al. N-Acylethanolamine Levels and Expression of Their

- Metabolizing Enzymes during Pregnancy. *Endocrinology* (2010).
229. Nomura, D. K. et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. *Cell* **140**, 49-61 (2010).
 230. Rask-Andersen, M., Olszewski, P. K., Levine, A. S. & Schioth, H. B. Molecular mechanisms underlying anorexia nervosa: focus on human gene association studies and systems controlling food intake. *Brain Res Rev* **62**, 147-164 (2010).
 231. Lee, T. Y., Lee, K. C. & Chang, H. H. Modulation of the cannabinoid receptors by andrographolide attenuates hepatic apoptosis following bile duct ligation in rats with fibrosis. *Apoptosis* (2010).
 232. Yang, Y. Y., Liu, H., Nam, S. W., Kunos, G. & Lee, S. S. Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids. *J Hepatol* **53**, 298-306 (2010).
 233. Van Ryckeghem, F. & Van Belle, S. Management of chemotherapy-induced nausea and vomiting. *Acta Clin Belg* **65**, 305-310 (2010).
 234. Laezza, C. et al. Inhibition of HMG-CoA reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cell. *Endocr Relat Cancer* (2010).
 235. Taylor, A. H., Abbas, M. S., Habiba, M. A. & Konje, J. C. Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human endometrium through the menstrual cycle. *Histochem Cell Biol* (2010).
 236. Thors, L. et al. Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. *PLoS One* **5**, e12275 (2010).
 237. Petrosino, S. & Di Marzo, V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. *Curr Opin Investig Drugs* **11**, 51-62 (2010).
 238. Berner, C. et al. Epigenetic Control of Estrogen Receptor Expression and Tumor Suppressor Genes Is Modulated by Bioactive Food Compounds. *Ann Nutr Metab* **57**, 183-189 (2010).
 239. Soneji, N. D., Paule, C. C., Mlynarczyk, M. & Nagy, I. Effects of cannabinoids on capsaicin receptor activity following exposure of primary sensory neurons to inflammatory mediators. *Life Sci* (2010).
 240. Linsalata, M. et al. Effects of anandamide on polyamine levels and cell growth in human colon cancer cells. *Anticancer Res* **30**, 2583-2589 (2010).
 241. Xian, X. S. et al. Effect of a synthetic cannabinoid agonist on the proliferation and invasion of gastric cancer cells. *J Cell Biochem* (2010).
 242. Kalifa, S., Polston, E. K., Allard, J. S. & Manaye, K. F. Distribution Patterns of Cannabinoid CB1 receptors in the hippocampus of APP(swe)/PS1(DeltaE9) double transgenic mice. *Brain Res* (2010).
 243. Martini, L., Thompson, D., Kharazia, V. & Whistler, J. L. Differential Regulation of Behavioral Tolerance to WIN55,212-2 by GASP1. *Neuropsychopharmacology* (2010).
 244. Posavad, C. M. et al. Detailed Characterization of T Cell Responses to Herpes Simplex Virus-2 in Immune Seronegative Persons. *J Immunol* (2010).
 245. Mingorance, C., de Sotomayor, M. A., Marhuenda, E. & Herrera, M. D. Chronic treatment with the cannabinoid 1 antagonist rimonabant altered vasoactive cyclo-

- oxygenase-derived products on arteries from obese Zucker rats. *J Cardiovasc Pharmacol* **56**, 560-569 (2010).
246. Ward, H., Luben, R. N., Wareham, N. J. & Khaw, K. T. CHD risk in relation to alcohol intake from categorical and open-ended dietary instruments. *Public Health Nutr* 1-8 (2010).
 247. Liu, W. M., Fowler, D. W. & Dalglish, A. G. Cannabis-Derived Substances in Cancer Therapy - an Emerging Anti-Inflammatory Role for the Cannabinoids. *Curr Clin Pharmacol* (2010).
 248. Carter, G. T., Abood, M. E., Aggarwal, S. K. & Weiss, M. D. Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. *Am J Hosp Palliat Care* **27**, 347-356 (2010).
 249. Caffarel, M. M. et al. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. *Mol Cancer* **9**, 196 (2010).
 250. Whyte, D. A. et al. Cannabinoids Inhibit Cellular Respiration of Human Oral Cancer Cells. *Pharmacology* **85**, 328-335 (2010).
 251. Reiss, C. S. Cannabinoids and Viral Infections. *Pharmaceuticals (Basel)* **3**, 1873-1886 (2010).
 252. Preet, A. et al. Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis. *Cancer Prev Res (Phila)* (2010).
 253. Brown, I. et al. Cannabinoid receptor dependent and independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor positive and negative prostate cancer cell lines. *Carcinogenesis* (2010).
 254. Larrinaga, G. et al. Cannabinoid CB1 Receptor Is Down-regulated in Clear Cell Renal Cell Carcinoma. *J Histochem Cytochem* (2010).
 255. Patel, K. D., Davison, J. S., Pittman, Q. J. & Sharkey, K. A. Cannabinoid CB(2) Receptors in Health and Disease. *Curr Med Chem* (2010).
 256. Marcu, J. P. et al. Cannabidiol enhances the inhibitory effects of Delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. *Mol Cancer Ther* **9**, 180-189 (2010).
 257. Paudel, K. S., Hammell, D. C., Agu, R. U., Valiveti, S. & Stinchcomb, A. L. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. *Drug Dev Ind Pharm* **36**, 1088-1097 (2010).
 258. LIU, D. Z., HU, C. M., HUANG, C. H., WEY, S. P. & JAN, T. R. Cannabidiol attenuates delayed-type hypersensitivity reactions via suppressing T-cell and macrophage reactivity. *Acta Pharmacol Sin* **31**, 1611-1617 (2010).
 259. Rajesh, M. et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. *J Am Coll Cardiol* **56**, 2115-2125 (2010).
 260. Cui, J. H. et al. Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model. *Neurosci Lett* (2010).
 261. Jordan, K. et al. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. *Support Care Cancer* (2010).
 262. Phillips, R. S. et al. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. *Cochrane Database Syst Rev* **9**, CD007786 (2010).

263. Nithipatikom, K., Isbell, M. A., Endsley, M. P., Woodliff, J. E. & Campbell, W. B. Anti-proliferative Effect of a Putative Endocannabinoid; 2-Arachidonylglycerol Ether in Prostate Carcinoma Cells. *Prostaglandins Other Lipid Mediat* (2010).
264. Marczylo, T. H., Lam, P. M., Amoako, A. A. & Konje, J. C. Anandamide levels in human female reproductive tissues: solid-phase extraction and measurement by ultraperformance liquid chromatography tandem mass spectrometry. *Anal Biochem* **400**, 155-162 (2010).
265. Yang, Q., Liu, H. Y., Zhang, Y. W., Wu, W. J. & Tang, W. X. Anandamide induces cell death through lipid rafts in hepatic stellate cells. *J Gastroenterol Hepatol* (2010).
266. Koo, J. S. & Jung, W. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1alpha regulation in human breast cancer. *Pathobiology* **77**, 289-300 (2010).
267. Park, J. Y. et al. Alcohol intake and risk of colorectal cancer: Results from the UK Dietary Cohort Consortium. *Br J Cancer* (2010).
268. Labar, G., Wouters, J. & Lambert, D. M. A Review on the Monoacylglycerol Lipase: At the Interface between Fat and Endocannabinoid Signalling. *Curr Med Chem* (2010).
269. Hsu, E. S. A review of granisetron, 5-hydroxytryptamine₃ receptor antagonists, and other antiemetics. *Am J Ther* **17**, 476-486 (2010).
270. Miro, A. M. et al. 17beta-Estradiol regulates oxidative stress in prostate cancer cell lines according to ERalpha/ERbeta ratio. *J Steroid Biochem Mol Biol* (2010).
271. Pisanti, S. et al. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. *Best Pract Res Clin Endocrinol Metab* **23**, 117-131 (2009).
272. El-Talatini, M. R., Taylor, A. H. & Konje, J. C. The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle. *Fertil Steril* (2009).
273. Guindon, J. & Hohmann, A. G. The Endocannabinoid System and Pain. *CNS Neurol Disord Drug Targets* (2009).
274. Leelawat, S., Leelawat, K., Narong, S. & Matangkasombut, O. The Dual Effects of Delta(9)-Tetrahydrocannabinol on Cholangiocarcinoma Cells: Anti-Invasion Activity at Low Concentration and Apoptosis Induction at High Concentration. *Cancer Invest* (2009).
275. Luca, T. et al. The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi's sarcoma cells in vitro. *Eur J Pharmacol* **616**, 16-21 (2009).
276. Olea-Herrero, N., Vara, D., Malagarie-Cazenave, S. & Diaz-Laviada, I. The cannabinoid R(+)-methanandamide induces IL-6 secretion by prostate cancer PC3 cells. *J Immunotoxicol* (2009).
277. Stubbs, M. & Griffiths, J. R. The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. *Adv Enzyme Regul* (2009).
278. Qamri, Z. et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. *Mol Cancer Ther* (2009).
279. Borrelli, F. & Izzo, A. A. Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. *Best Pract Res Clin Endocrinol Metab* **23**, 33-49 (2009).
280. Santoro, A. et al. Rimonabant inhibits human colon cancer cell growth and reduces

- the formation of precancerous lesions in the mouse colon. *Int J Cancer* (2009).
281. Furuse, S. et al. Reduction of Bone Cancer Pain by Activation of Spinal Cannabinoid Receptor 1 and Its Expression in the Superficial Dorsal Horn of the Spinal Cord in a Murine Model of Bone Cancer Pain. *Anesthesiology* (2009).
 282. Wang, Q. et al. Pretreatment With Electroacupuncture Induces Rapid Tolerance to Focal Cerebral Ischemia Through Regulation of Endocannabinoid System. *Stroke* (2009).
 283. Schley, M. et al. Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. *Brain Res Bull* **79**, 333-337 (2009).
 284. Gustafsson, K., Sander, B., Bielawski, J., Hannun, Y. A. & Flygare, J. Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism. *Mol Cancer Res* **7**, 1086-1098 (2009).
 285. Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V. & Mechoulam, R. Non-psychoactive plant cannabinoids: new therapeutic opportunities from an ancient herb. *Trends Pharmacol Sci* (2009).
 286. Surtees, P. G., Wainwright, N. W., Luben, R. N., Khaw, K. T. & Bingham, S. A. No evidence that social stress is associated with breast cancer incidence. *Breast Cancer Res Treat* (2009).
 287. Surtees, P. G. et al. No association between APOE and major depressive disorder in a community sample of 17,507 adults. *J Psychiatr Res* (2009).
 288. Brizzi, A. et al. New Resorcinol-Anandamide "Hybrids" as Potent Cannabinoid Receptor Ligands Endowed with Antinociceptive Activity in Vivo. *J Med Chem* (2009).
 289. Wegener, N. & Koch, M. Neurobiology and Systems Physiology of the Endocannabinoid System. *Pharmacopsychiatry* **42**, S79-S86 (2009).
 290. Keeley, P. W. Nausea and vomiting in people with cancer and other chronic diseases. *Clin Evid (Online)* **2009**, (2009).
 291. Galal, A. M. et al. Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications. *Recent Pat CNS Drug Discov* **4**, 112-136 (2009).
 292. Johnson, J. R. et al. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients With Intractable Cancer-Related Pain. *J Pain Symptom Manage* (2009).
 293. Takeda, S., Yamamoto, I. & Watanabe, K. Modulation of Delta(9)-tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase. *Toxicology* **259**, 25-32 (2009).
 294. Van Dross, R. T. Metabolism of anandamide by COX-2 is necessary for endocannabinoid-induced cell death in tumorigenic keratinocytes. *Mol Carcinog* (2009).
 295. Berthiller, J. et al. Marijuana Smoking and the Risk of Head and Neck Cancer: Pooled Analysis in the INHANCE Consortium. *Cancer Epidemiol Biomarkers Prev* **18**, 1544-1551 (2009).
 296. El-Talatini, M. R. et al. Localisation and function of the endocannabinoid system in the human ovary. *PLoS ONE* **4**, e4579 (2009).
 297. Yin, H. et al. Lipid G-protein-coupled Receptor Ligand Identification Using beta -

- arrestin Pathhunter Assay. *J Biol Chem* (2009).
298. Yin, H. et al. Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. *J Biol Chem* **284**, 12328-12338 (2009).
 299. De Filippis, D. et al. LEVELS OF ENDOCANNABINOIDS AND PALMITOYLETHANOLAMIDE AND THEIR PHARMACOLOGICAL MANIPULATION IN CHRONIC GRANULOMATOUS INFLAMMATION IN RATS. *Pharmacol Res* (2009).
 300. Tournier, N. et al. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). *Int J Neuropsychopharmacol* 1-11 (2009).
 301. Olea-Herrero, N., Vara, D., Malagarie-Cazenave, S. & Diaz-Laviada, I. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB(2). *Br J Cancer* (2009).
 302. El-Talatini, M. R., Taylor, A. H. & Konje, J. C. Fluctuation in anandamide levels from ovulation to early pregnancy in in-vitro fertilization-embryo transfer women, and its hormonal regulation. *Hum Reprod* (2009).
 303. Moayyeri, A. et al. Estimation of absolute fracture risk among middle-aged and older men and women: the EPIC-Norfolk population cohort study. *Eur J Epidemiol* (2009).
 304. Pisanti, S. & Bifulco, M. Endocannabinoid system modulation in cancer biology and therapy. *Pharmacol Res* **60**, 107-116 (2009).
 305. Pertwee, R. G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. *Br J Pharmacol* **156**, 397-411 (2009).
 306. Gao, F. F. et al. Egr-1, a central and unifying role in cardioprotection from ischemia-reperfusion injury? *Cell Physiol Biochem* **24**, 519-526 (2009).
 307. Cotter, J. Efficacy of Crude Marijuana and Synthetic Delta-9-Tetrahydrocannabinol as Treatment for Chemotherapy-Induced Nausea and Vomiting: A Systematic Literature Review. *Oncol Nurs Forum* **36**, 345-352 (2009).
 308. Farquhar-Smith, W. P. Do cannabinoids have a role in cancer pain management? *Curr Opin Support Palliat Care* **3**, 7-13 (2009).
 309. Udler, M. S. et al. Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. *Int J Cancer* (2009).
 310. Brighton, P. J. et al. Characterization of anandamide-stimulated cannabinoid receptor signaling in human ULTR myometrial smooth muscle cells. *Mol Endocrinol* (2009).
 311. Bifulco, M., Santoro, A., Laezza, C. & Malfitano, A. M. Chapter 7 Cannabinoid Receptor CB1 Antagonists State of the Art and Challenges. *Vitam Horm* **81**, 159-189 (2009).
 312. Alpini, G. & Demorrow, S. Chapter 18 Changes in the Endocannabinoid System May Give Insight into new and Effective Treatments for Cancer. *Vitam Horm* **81C**, 469-485 (2009).
 313. Villanueva, A. et al. Central Cannabinoid-1 Receptor Antagonist Administration Prevents Endotoxic Hypotension Affecting Norepinephrine Release in the Preoptic Anterior Hypothalamic Area. *Shock* (2009).
 314. Han, K. H. et al. CB1 and CB2 Cannabinoid Receptors Differentially Regulate the

- Production of Reactive Oxygen Species by Macrophages. *Cardiovasc Res* (2009).
315. Froger, N. et al. Cannabinoids prevent the opposite regulation of astroglial connexin43 hemichannels and gap junction channels induced by pro-inflammatory treatments. *J Neurochem* **111**, 1383-1397 (2009).
 316. Alexander, A., Smith, P. F. & Rosengren, R. J. Cannabinoids in the treatment of cancer. *Cancer Lett* **285**, 6-12 (2009).
 317. Izzo, A. A. & Camilleri, M. Cannabinoids in intestinal inflammation and cancer. *Pharmacol Res* (2009).
 318. Oesch, S. & Gertsch, J. Cannabinoid receptor ligands as potential anticancer agents - high hopes for new therapies? *J Pharm Pharmacol* **61**, 839-853 (2009).
 319. Zhao, P., Leonoudakis, D., Abood, M. E. & Beattie, E. Cannabinoid Receptor Activation Reduces TNFalpha-Induced Surface Localization of AMPAR-Type Glutamate Receptors and Excitotoxicity. *Neuropharmacology* (2009).
 320. Oesch, S. et al. Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. *Mol Cancer Ther* (2009).
 321. Salazar, M. et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. *J Clin Invest* (2009).
 322. Ramer, R., Merkord, J., Rohde, H. & Hinz, B. Cannabidiol Inhibits Cancer Cell Invasion Via Upregulation Of Tissue Inhibitor Of Matrix Metalloproteinases-1. *Biochem Pharmacol* (2009).
 323. Napimoga, M. H. et al. Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats. *Int Immunopharmacol* **9**, 216-222 (2009).
 324. Magen, I. et al. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. *J Hepatol* **51**, 528-534 (2009).
 325. Mantovani, G. & Madeddu, C. Cancer cachexia: medical management. *Support Care Cancer* (2009).
 326. Gallant, M., Odei-Addo, F., Frost, C. L. & Levendal, R. A. Biological effects of THC and a lipophilic cannabis extract on normal and insulin resistant 3T3-L1 adipocytes. *Phytomedicine* (2009).
 327. Daling, J. R. et al. Association of marijuana use and the incidence of testicular germ cell tumors. *Cancer* (2009).
 328. Dunning, A. M. et al. Association of ESR1 gene tagging SNPs with breast cancer risk. *Hum Mol Genet* (2009).
 329. Freimuth, N., Ramer, R. & Hinz, B. Antitumorigenic effects of cannabinoids beyond apoptosis. *J Pharmacol Exp Ther* (2009).
 330. Murakami, T. et al. Antimicrobial cathelicidin polypeptide CAP11 suppresses the production and release of septic mediators in D-galactosamine-sensitized endotoxin shock mice. *Int Immunol* (2009).
 331. Navari, R. M. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. *Expert Opin Pharmacother* **10**, 629-644 (2009).
 332. Kingsley, P. J. & Marnett, L. J. Analysis of endocannabinoids, their congeners and COX-2 metabolites. *J Chromatogr B Analyt Technol Biomed Life Sci* (2009).
 333. Madeddu, C. & Mantovani, G. An update on promising agents for the treatment of cancer cachexia. *Curr Opin Support Palliat Care* (2009).
 334. Lorente, M. et al. Amphiregulin is a factor for resistance of glioma cells to

- cannabinoid-induced apoptosis. *Glia* (2009).
335. Liang, C. et al. A Population-Based Case-Control Study of Marijuana Use and Head and Neck Squamous Cell Carcinoma. *Cancer Prev Res (Phila Pa)* (2009).
336. Ernst, G. & Kongsgaard, U. E. [Use of cannabinoids in palliative medicine.]. *Tidsskr Nor Laegeforen* **128**, 822-825 (2008).
337. Lam, P. M. et al. Ultra Performance Liquid Chromatography Tandem Mass Spectrometry Method for the Measurement of Anandamide in Human Plasma. *Anal Biochem* (2008).
338. Bari, M. et al. Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells. *Neuropharmacology* **54**, 45-50 (2008).
339. DUBOIS. Turned-off Cannabinoid Receptor Turns on Colorectal Tumor Growth. *Newswise* (2008).
340. Machado Rocha, F. C., Stefano, S. C., DE Cassia Haiek, R., Rosa Oliveira, L. M. & DA Silveira, D. X. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. *Eur J Cancer Care (Engl)* (2008).
341. Rudolph, M. I. et al. The Influence of Mast Cell Mediators on Migration of SW756 Cervical Carcinoma Cells. *J Pharmacol Sci* **106**, 208-218 (2008).
342. Bilsland, L. G. & Greensmith, L. The endocannabinoid system in amyotrophic lateral sclerosis. *Curr Pharm Des* **14**, 2306-2316 (2008).
343. Lissoni, P. et al. The endocannabinoid anandamide neither impairs in vitro T-cell function nor induces regulatory T-cell generation. *Anticancer Res* **28**, 3743-3748 (2008).
344. Demorrow, S. et al. Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation. *Am J Physiol Gastrointest Liver Physiol* **294**, G506-G519 (2008).
345. Coffman, K. L. The debate about marijuana usage in transplant candidates: recent medical evidence on marijuana health effects. *Curr Opin Organ Transplant* **13**, 189-195 (2008).
346. Zheng, D. et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. *Cancer Res* **68**, 3992-3998 (2008).
347. Potenzieri, C., Harding-Rose, C. & Simone, D. A. The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. *Brain Res* (2008).
348. Laezza, C., Pisanti, S., Malfitano, A. M. & Bifulco, M. The anandamide analogue, Met-F-AEA, controls human breast cancer cell migration via the RhoA/Rho kinase signaling pathway. *Endocr Relat Cancer* (2008).
349. Dahlstrom, K. R. et al. Squamous cell carcinoma of the head and neck in never smoker-never drinkers: a descriptive epidemiologic study. *Head Neck* **30**, 75-84 (2008).
350. Kerr, J. R. et al. Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. *J Clin Pathol* **61**, 730-739 (2008).
351. Rahn, E. J. et al. Selective Activation of Cannabinoid CB2 Receptors Suppresses Neuropathic Nociception Induced by Treatment with the Chemotherapeutic Agent Paclitaxel in Rats. *J Pharmacol Exp Ther* (2008).

352. Santoro, A. et al. Reply to the letter to the editor "Long-term cannabinoid receptor (CB1) blockade in obesity: Implications for the development of colorectal cancer". *Int J Cancer* (2008).
353. Eichele, K., Ramer, R. & Hinz, B. R(+)-Methanandamide-Induced Apoptosis of Human Cervical Carcinoma Cells Involves A Cyclooxygenase-2-Dependent Pathway. *Pharm Res* (2008).
354. Surtees, P. G. et al. Psychological distress, major depressive disorder, and risk of stroke. *Neurology* **70**, 788-794 (2008).
355. van Diepen, H., Schlicker, E. & Michel, M. C. Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). *Naunyn Schmiedebergs Arch Pharmacol* (2008).
356. De Petrocellis, L. et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. *J Pharmacol Exp Ther* **325**, 1007-1015 (2008).
357. De Petrocellis, L. et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 (TRPA1) and melastatin type-8 (TRPM-8). *J Pharmacol Exp Ther* (2008).
358. Alfranca, A. et al. PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFbeta/Alk5 signaling pathway. *Blood* **112**, 1120-1128 (2008).
359. El-Remessy, A. B. et al. Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. *Mol Vis* **14**, 2190-2203 (2008).
360. Liou, G. I. et al. Mediation of Cannabidiol Anti-inflammation in the Retina by Equilibrative Nucleoside Transporter and A2A Adenosine Receptor. *Invest Ophthalmol Vis Sci* (2008).
361. Wang, D. et al. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. *Cancer Res* **68**, 6468-6476 (2008).
362. Caffarel, M. M. et al. JunD is involved in the antiproliferative effect of Delta(9)-tetrahydrocannabinol on human breast cancer cells. *Oncogene* (2008).
363. Ramer, R. & Hinz, B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. *J Natl Cancer Inst* **100**, 59-69 (2008).
364. Czifra, G. et al. Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. *J Cancer Res Clin Oncol* (2008).
365. Chen, A. L. et al. Hypothesizing that marijuana smokers are at a significantly lower risk of carcinogenicity relative to tobacco-non-marijuana smokers: evidenced based on statistical reevaluation of current literature. *J Psychoactive Drugs* **40**, 263-272 (2008).
366. Widmer, M., Hanemann, O. & Zajicek, J. High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells. *J Neurosci Res* (2008).
367. Habayeb, O. M., Taylor, A. H., Bell, S. C., Taylor, D. J. & Konje, J. C. Expression of the Endocannabinoid System in Human First Trimester Placenta and its Role in Trophoblast Proliferation. *Endocrinology* (2008).
368. Gustafsson, K. et al. Expression of Cannabinoid Receptors Type 1 and Type 2 in Non-hodkin Lymphoma: Growth Inhibition By Receptor Activation. *Int J Cancer*

- (2008).
369. Wang, J. et al. Expression and secretion of N-acyl ethanolamine-hydrolyzing acid amidase in human prostate cancer cells. *J Biochem* (2008).
 370. Massi, P., Valenti, M., Bolognini, D. & Parolaro, D. Expression and function of the endocannabinoid system in glial cells. *Curr Pharm Des* **14**, 2289-2298 (2008).
 371. Endsley, M. P. et al. Expression and Function of Fatty Acid Amide Hydrolase in Prostate Cancer. *Int J Cancer* (2008).
 372. Notarnicola, M. et al. Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines. *Scand J Gastroenterol* **43**, 66-72 (2008).
 373. Yazulla, S. Endocannabinoids in the retina: From marijuana to neuroprotection. *Prog Retin Eye Res* (2008).
 374. Bifulco, M., Malfitano, A. M., Pisanti, S. & Laezza, C. Endocannabinoids in endocrine and related tumours. *Endocr Relat Cancer* **15**, 391-408 (2008).
 375. Blazquez, C. et al. Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity? *Neuropharmacology* **54**, 235-243 (2008).
 376. Fowler, C. J. & Ghafouri, N. Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake? *Pharmacol Res* (2008).
 377. von Bueren, A. O., Schlumpf, M. & Lichtensteiger, W. Delta(9)-tetrahydrocannabinol inhibits 17beta-estradiol-induced proliferation and fails to activate androgen and estrogen receptors in MCF7 human breast cancer cells. *Anticancer Res* **28**, 85-89 (2008).
 378. Galanti, G. et al. Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. *Acta Oncol* **47**, 1062-1070 (2008).
 379. Deutsch, S. I. et al. Current Status of Cannabis Treatment of Multiple Sclerosis with an Illustrative Case Presentation of a Patient with MS, Complex Vocal Tics, Paroxysmal Dystonia, and Marijuana Dependence Treated with Dronabinol. *CNS Spectr* **13**, 393-403 (2008).
 380. Warr, D. G. Chemotherapy- and cancer-related nausea and vomiting. *Curr Oncol* **15**, S4-S9 (2008).
 381. Brambilla, C. & Colonna, M. Cannabis: the next villain on the lung cancer battlefield? *Eur Respir J* **31**, 227-228 (2008).
 382. Aldington, S. et al. Cannabis use and risk of lung cancer: a case-control study. *Eur Respir J* **31**, 280-286 (2008).
 383. Aldington, S. et al. Cannabis use and cancer of the head and neck: case-control study. *Otolaryngol Head Neck Surg* **138**, 374-380 (2008).
 384. Van der Kooy, F., Pomahacova, B. & Verpoorte, R. Cannabis Smoke Condensate II: Influence of Tobacco on Tetrahydrocannabinol Levels. *Inhal Toxicol* **1** (2008).
 385. Blazquez, C. et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. *Cancer Res* **68**, 1945-1952 (2008).
 386. Russo, E. B. Cannabinoids in the management of difficult to treat pain. *Ther Clin Risk Manag* **4**, 245-259 (2008).
 387. Sarfaraz, S., Adhami, V. M., Syed, D. N., Afaq, F. & Mukhtar, H. Cannabinoids for cancer treatment: progress and promise. *Cancer Res* **68**, 339-342 (2008).
 388. Iribarne, M. et al. Cannabinoid Receptors in Conjunctival Epithelium: Identification

- and Functional Properties. *Invest Ophthalmol Vis Sci* (2008).
389. Jones, J. D., Carney, S. T., Vrana, K. E., Norford, D. C. & Howlett, A. C. Cannabinoid receptor-mediated translocation of NO-sensitive guanylyl cyclase and production of cyclic GMP in neuronal cells. *Neuropharmacology* **54**, 23-30 (2008).
 390. Gustafsson, S. B., Lindgren, T., Jonsson, M. & Jacobsson, S. O. Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. *Cancer Chemother Pharmacol* (2008).
 391. Anand, P., Whiteside, G., Fowler, C. J. & Hohmann, A. G. Targeting CB(2) receptors and the endocannabinoid system for the treatment of pain. *Brain Res Rev* (2008).
 392. Cianchi, F. et al. Cannabinoid Receptor Activation Induces Apoptosis through Tumor Necrosis Factor α -Mediated Ceramide De novo Synthesis in Colon Cancer Cells. *Clin Cancer Res* **14**, 7691-7700 (2008).
 393. Shi, Y. et al. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. *Cancer Gene Ther* **15**, 101-107 (2008).
 394. Zuardi, A. W. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. *Rev Bras Psiquiatr* **30**, 271-280 (2008).
 395. Weiss, L. et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. *Neuropharmacology* **54**, 244-249 (2008).
 396. Roderick, H. L. & Cook, S. J. Ca²⁺ signalling checkpoints in cancer: remodelling Ca²⁺ for cancer cell proliferation and survival. *Nat Rev Cancer* **8**, 361-375 (2008).
 397. Giuliano, M. et al. Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: Involvement of the transcription factor PPAR γ . *Biochimie* (2008).
 398. Buznikov, G. A. et al. Amyloid Precursor Protein 96-110 and Beta-amyloid 1-42 Elicit Developmental Anomalies in Sea Urchin Embryos and Larvae That Are Alleviated By Neurotransmitter Analogs for Acetylcholine, Serotonin and Cannabinoids. *Neurotoxicol Teratol* (2008).
 399. Stebulis, J. A., Johnson, D. R., Rossetti, R. G., Burstein, S. H. & Zurier, R. B. Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. *Life Sci* **83**, 666-670 (2008).
 400. Sugamura, K. et al. Activated Endocannabinoid System in Coronary Artery Disease and Antiinflammatory Effects of Cannabinoid 1 Receptor Blockade on Macrophages. *Circulation* (2008).
 401. Marczylo, T. H., Lam, P. M., Nallendran, V., Taylor, A. H. & Konje, J. C. A solid-phase method for the extraction and measurement of anandamide from multiple human biomatrices. *Anal Biochem* (2008).
 402. Ware, M. A., Daeninck, P. & Maida, V. A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. *Ther Clin Risk Manag* **4**, 99-107 (2008).
 403. Chung, S. C. et al. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. *Eur J Cancer* (2008).
 404. Khasabova, I. A. et al. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain.

- J Neurosci* **28**, 11141-11152 (2008).
405. Diaz, P. et al. 6-Methoxy-N-alkyl Isatin Acylhydrazone Derivatives as a Novel Series of Potent Selective Cannabinoid Receptor 2 Inverse Agonists: Design, Synthesis, and Binding Mode Prediction. *J Med Chem* (2008).
 406. Massi, P. et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. *J Neurochem* **104**, 1091-1100 (2008).
 407. Gkoumassi, E. et al. Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells. *Br J Pharmacol* (2007).
 408. Taylor, A. H., Ang, C., Bell, S. C. & Konje, J. C. The role of the endocannabinoid system in gametogenesis, implantation and early pregnancy. *Hum Reprod Update* (2007).
 409. Whiteside, G. T., Lee, G. P. & Valenzano, K. J. The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. *Curr Med Chem* **14**, 917-936 (2007).
 410. Holland, M. L., Lau, D. T., Allen, J. D. & Arnold, J. C. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. *Br J Pharmacol* (2007).
 411. Flygare, J. & Sander, B. The endocannabinoid system in cancer-Potential therapeutic target? *Semin Cancer Biol* (2007).
 412. Greenhough, A., Patsos, H. A., Williams, A. C. & Paraskeva, C. The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. *Int J Cancer* (2007).
 413. Izzo, A. A. The cannabinoid CB(2) receptor: a good friend in the gut. *Neurogastroenterol Motil* **19**, 704-708 (2007).
 414. Johnson, D. R., Stebulis, J. A., Rossetti, R. G., Burstein, S. H. & Zurier, R. B. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. *J Cell Biochem* **100**, 184-190 (2007).
 415. Bifulco, M., Grimaldi, C., Gazzerò, P., Pisanti, S. & Santoro, A. Rimonabant: Just an Anti-obesity Drug? Current Evidence on Its Pleiotropic Effects. *Mol Pharmacol* (2007).
 416. Gary-Bobo, M. et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. *Hepatology* (2007).
 417. Darmani, N. A., Janoyan, J. J., Crim, J. & Ramirez, J. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew. *Eur J Pharmacol S* (2007).
 418. Demorrow, S. et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth: Recruitment of fas and fas ligand to lipid rafts. *J Biol Chem S* (2007).
 419. Engels, F. K. et al. Medicinal cannabis in oncology. *Eur J Cancer* **43**, 2638-2644 (2007).
 420. Seamon, M. J., Fass, J. A., Maniscalco-Feichtl, M. & Abu-Shraie, N. A. Medical marijuana and the developing role of the pharmacist. *Am J Health Syst Pharm* **64**, 1037-1044 (2007).
 421. Fogarty, A. et al. Marijuana as therapy for people living with HIV/AIDS: Social and health aspects. *AIDS Care S* **19**, 295-301 (2007).
 422. De Filippis, D. et al. Local administration of WIN 55,212-2 reduces chronic

- granuloma-associated angiogenesis in rat by inhibiting NF-kappaB activation. *J Mol Med* (2007).
423. Kingsley, P. J. & Marnett, L. J. LC-MS-MS Analysis of Neutral Eicosanoids. *Methods Enzymol* **433**, 91-112 (2007).
424. Varvel, S. A., Martin, B. R. & Lichtman, A. H. Lack of behavioral sensitization after repeated exposure to THC in mice and comparison to methamphetamine. *Psychopharmacology (Berl)* (2007).
425. Thors, L., Alajakku, K. & Fowler, C. J. The 'specific' tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake. *Br J Pharmacol* (2007).
426. Tham, C. S., Whitaker, J., Luo, L. & Webb, M. Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators. *FEBS Lett* **581**, 2899-2904 (2007).
427. Izzo, A. A. et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. *J Mol Med* (2007).
428. Kempf, K. et al. Immune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity. *Horm Metab Res* **39**, 596-600 (2007).
429. Vila, A., Rosengarth, A., Piomelli, D., Cravatt, B. & Marnett, L. J. Hydrolysis of Prostaglandin Glycerol Esters by the Endocannabinoid-Hydrolyzing Enzymes, Monoacylglycerol Lipase and Fatty Acid Amide Hydrolase. *Biochemistry* (2007).
430. Peters, M. & Kogan, N. M. HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity. *Expert Opin Investig Drugs* **16**, 1405-1413 (2007).
431. Bifulco, M., Laezza, C., Gazerro, P. & Pentimalli, F. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (Review). *Oncol Rep* **17**, 813-816 (2007).
432. Mukhopadhyay, S. & Tulis, D. A. Endocannabinoid regulation of matrix metalloproteinases: implications in ischemic stroke. *Cardiovasc Hematol Agents Med Chem* **5**, 311-318 (2007).
433. Sunil K. Aggarwal, M. S. I. I. I., PhC, BS, BA; Muraco Kyashna-Tocha, PhD; Gregory T. Carter, MD, MS. Dosing Medical Marijuana: Rational Guidelines on Trial in Washington State. (2007).
434. Endsley, M. P. et al. Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism. *Int J Cancer* (2007).
435. Schramm-Sapyta, N. L. et al. Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. *Psychopharmacology (Berl)* **5** (2007).
436. Preet, A., Ganju, R. K. & Groopman, J. E. Delta(9)-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. *Oncogene* (2007).
437. Takeda, S. et al. Delta(9)-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling. *Toxicology* (2007).
438. Batkai, S. et al. Decreased age-related cardiac dysfunction, myocardial oxidative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. *Am J Physiol Heart Circ Physiol* **293**, H909-H918 (2007).
439. Jordan, K., Schmoll, H. J. & Aapro, M. S. Comparative activity of antiemetic drugs.

Crit Rev Oncol Hematol S (2007).

440. Udler, M. et al. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. *J Clin Oncol* **25**, 3015-3023 (2007).
441. Russo, E. B., Guy, G. W. & Robson, P. J. Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex((R)), a Cannabis-Based Medicine. *Chem Biodivers* **4**, 1729-1743 (2007).
442. Aguado, T. et al. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. *J Biol Chem S* (2007).
443. Slatkin, N. E. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. *J Support Oncol* **5**, 1-9 (2007).
444. Michalski, C. W. et al. Cannabinoids in pancreatic cancer: Correlation with survival and pain. *Int J Cancer* (2007).
445. Kogan, N. M. & Mechoulam, R. Cannabinoids in health and disease. *Dialogues Clin Neurosci* **9**, 413-430 (2007).
446. D'Souza, D. C. Cannabinoids and psychosis. *Int Rev Neurobiol S* **78**, 289-326 (2007).
447. Velasco, G. et al. Cannabinoids and gliomas. *Mol Neurobiol* **36**, 60-67 (2007).
448. Athanasiou, A. et al. Cannabinoid receptor agonists are mitochondrial inhibitors: A unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. *Biochem Biophys Res Commun* **364**, 131-137 (2007).
449. Zhang, X., Wang, J. F., Kunos, G. & Groopman, J. E. Cannabinoid Modulation of Kaposi's Sarcoma Associated Herpesvirus Infection and Transformation. *Cancer Res* **67**, 7230-7237 (2007).
450. McAllister, S. D., Christian, R. T., Horowitz, M. P., Garcia, A. & Desprez, P. Y. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. *Mol Cancer Ther* **6**, 2921-2927 (2007).
451. Vidinsky, B., Gal, P. & Mojzis, J. [Different views on the association between cannabinoids and cancer]. *Cas Lek Cesk* **145**, 453-7; discussion 458 (2006).
452. Vignot, S. et al. [Cannabis and cancer]. *Bull Cancer* **93**, 163-170 (2006).
453. Verhoeckx, K. C. et al. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. *Int Immunopharmacol* **6**, 656-665 (2006).
454. Stokes, A. et al. TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. *Cell Signal* **18**, 1584-1594 (2006).
455. Singh, J. & Budhiraja, S. Therapeutic potential of cannabinoid receptor ligands: current status. *Methods Find Exp Clin Pharmacol* **28**, 177-183 (2006).
456. Carracedo, A. et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. *Cancer Cell* **9**, 301-312 (2006).
457. Massi, P. et al. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. *Cell Mol Life Sci* (2006).
458. Pacher, P., Batkai, S. & Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol Rev* **58**, 389-462 (2006).
459. Davis, M., Maida, V., Daeninck, P. & Pergolizzi, J. The emerging role of cannabinoid neuromodulators in symptom management. *Support Care Cancer* (2006).
460. Holland, M. L. et al. The effects of cannabinoids on P-glycoprotein transport and

- expression in multidrug resistant cells. *Biochem Pharmacol* **71**, 1146-1154 (2006).
461. Herrera, B. et al. The CB(2) cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. *Exp Cell Res* (2006).
 462. Sarnataro, D. et al. The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Human Breast Cancer Cell Proliferation Through A Lipid Rafts Mediated Mechanism. *Mol Pharmacol* (2006).
 463. Mehra, R., Moore, B. A., Crothers, K., Tetrault, J. & Fiellin, D. A. The association between marijuana smoking and lung cancer: a systematic review. *Arch Intern Med* **166**, 1359-1367 (2006).
 464. Roberts, J. D., Gennings, C. & Shih, M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. *Eur J Pharmacol* **530**, 54-58 (2006).
 465. Eichele, K., Weinzierl, U., Ramer, R., Brune, K. & Hinz, B. R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells. *Pharm Res* **23**, 90-94 (2006).
 466. Fernandez-Solari, J., Prestifilippo, J. P., Bornstein, S. R., McCann, S. M. & Rettori, V. Participation of the Endocannabinoid System in the Effect of TNF- α on Hypothalamic Release of Gonadotropin-Releasing Hormone. *Ann N Y Acad Sci S* **1088**, 238-250 (2006).
 467. Goanvic, D. L. & Tius, M. A. Oxaza adamantyl cannabinoids. A new class of cannabinoid receptor probes. *J Org Chem* **71**, 7800-7804 (2006).
 468. Xu, X. et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. *Cancer Genet Cytogenet* **171**, 31-38 (2006).
 469. Bari, M., Battista, N., Fezza, F., Gasperi, V. & Maccarrone, M. New insights into endocannabinoid degradation and its therapeutic potential. *Mini Rev Med Chem* **6**, 257-268 (2006).
 470. Ben-Shabat, S., Hanus, L. O., Katzavian, G. & Gallily, R. New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. *J Med Chem* **49**, 1113-1117 (2006).
 471. El-Remessy, A. B. et al. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. *Am J Pathol* **168**, 235-244 (2006).
 472. Guagnini, F. et al. Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. *Gut* **55**, 946-953 (2006).
 473. Hashibe, M. et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. *Cancer Epidemiol Biomarkers Prev* **15**, 1829-1834 (2006).
 474. Thors, L. & Fowler, C. J. Is there a temperature-dependent uptake of anandamide into cells? *Br J Pharmacol* **149**, 73-81 (2006).
 475. Rao, G. K. & Kaminski, N. E. Induction of intracellular calcium elevation by Delta9-tetrahydrocannabinol in T cells involves TRPC1 channels. *J Leukoc Biol* **79**, 202-213 (2006).
 476. Alsasua Del Valle, A. Implication of Cannabinoids in Neurological Diseases. *Cell Mol Neurobiol* (2006).
 477. Ziring, D. et al. Formation of B and T cell subsets require the cannabinoid receptor

- CB2. *Immunogenetics* **58**, 714-725 (2006).
478. Wang, H. et al. Fatty acid amide hydrolase deficiency limits early pregnancy events. *J Clin Invest* **116**, 2122-2131 (2006).
479. Berlach, D. M., Shir, Y. & Ware, M. A. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. *Pain Med* **7**, 25-29 (2006).
480. Melamede, R. J. Endocannabinoids: Multi-scaled, Global Homeostatic Regulators of Cells and Society. *Interjournal Complex Systems* 1669 (2006).
481. Stein, L. A. et al. Effects of motivational interviewing for incarcerated adolescents on driving under the influence after release. *Am J Addict* **15 Suppl 1**, 50-57 (2006).
482. Ellert-Miklaszewska, A., Grajkowska, W., Gabrusiewicz, K., Kaminska, B. & Konarska, L. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. *Brain Res S* (2006).
483. Huang, H., Nishi, K., Tsai, H. J. & Hammock, B. D. Development of highly sensitive fluorescent assays for fatty acid amide hydrolase. *Anal Biochem SO - Anal Biochem. 2006 Dec 20;d* (2006).
484. Jia, W. et al. Delta⁹-Tetrahydrocannabinol-Induced Apoptosis in Jurkat Leukemia T Cells Is Regulated by Translocation of Bad to Mitochondria. *Mol Cancer Res* **4**, 549-562 (2006).
485. Caffarel, M. M., Sarrío, D., Palacios, J., Guzman, M. & Sanchez, C. Delta⁹-Tetrahydrocannabinol Inhibits Cell Cycle Progression in Human Breast Cancer Cells through Cdc2 Regulation. *Cancer Res* **66**, 6615-6621 (2006).
486. Shmist, Y. A. et al. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. *Mol Cell Biochem* **283**, 75-83 (2006).
487. Strasser, F. et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. *J Clin Oncol* **24**, 3394-3400 (2006).
488. Perez, J. Combined cannabinoid therapy via an oromucosal spray. *Drugs Today (Barc)* **42**, 495-503 (2006).
489. Fernandez-Lopez, D. et al. Characterization of the Neuroprotective Effect of the Cannabinoid Agonist WIN-55212 in an In Vitro Model of Hypoxic-Ischemic Brain Damage in Newborn Rats. *Pediatr Res* (2006).
490. Massi, P., Vaccani, A. & Parolaro, D. Cannabinoids, immune system and cytokine network. *Curr Pharm Des* **12**, 3135-3146 (2006).
491. Carracedo, A. et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. *Cancer Res* **66**, 6748-6755 (2006).
492. Ben Amar, M. Cannabinoids in medicine: A review of their therapeutic potential. *J Ethnopharmacol* **105**, 1-25 (2006).
493. Huskey, A. Cannabinoids in cancer pain management. *J Pain Palliat Care Pharmacother* **20**, 43-46 (2006).
494. Bifulco, M., Laezza, C., Pisanti, S. & Gazerro, P. Cannabinoids and cancer: pros and cons of an antitumour strategy. *Br J Pharmacol* **148**, 123-135 (2006).
495. Mormina, M. E., Thakur, S., Molleman, A., Whelan, C. J. & Baydoun, A. R. Cannabinoid signalling in TNF-alpha induced IL-8 release. *Eur J Pharmacol* (2006).

496. Held-Feindt, J., Dorner, L., Sahan, G., Mehdorn, H. M. & Mentlein, R. Cannabinoid receptors in human astroglial tumors. *J Neurochem* **98**, 886-893 (2006).
497. Blazquez, C. et al. Cannabinoid receptors as novel targets for the treatment of melanoma. *FASEB J* (2006).
498. Sarfaraz, S., Afaq, F., Adhami, V. M., Malik, A. & Mukhtar, H. Cannabinoid receptor agonist induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. *J Biol Chem* (2006).
499. Karanian, D. A. & Bahr, B. A. Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states. *Curr Mol Med* **6**, 677-684 (2006).
500. Fogli, S. et al. Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. *FEBS Lett* **580**, 1733-1739 (2006).
501. McKallip, R. J. et al. Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression. *Mol Pharmacol* **70**, 897-908 (2006).
502. Weiss, L. et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. *Autoimmunity* **39**, 143-151 (2006).
503. Chacko, J. A., Heiner, J. G., Siu, W., Macy, M. & Terris, M. K. Association between marijuana use and transitional cell carcinoma. *Urology* **67**, 100-104 (2006).
504. Pisanti, S. et al. Antiangiogenic activity of the endocannabinoid anandamide: Correlation to its tumor-suppressor efficacy. *J Cell Physiol S* (2006).
505. Ligresti, A. et al. Anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *J Pharmacol Exp Ther* (2006).
506. Laezza, C., Simona, P., Crescenzi, E. & Bifulco, M. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. *FEBS Lett* **580**, 6076-6082 (2006).
507. Grimaldi, C. et al. Anandamide inhibits adhesion and migration of breast cancer cells. *Exp Cell Res* **312**, 363-373 (2006).
508. Raduner, S. et al. Alkylamides from Echinacea Are a New Class of Cannabinomimetics: CANNABINOID TYPE 2 RECEPTOR-DEPENDENT AND -INDEPENDENT IMMUNOMODULATORY EFFECTS. *J Biol Chem* **281**, 14192-14206 (2006).
509. De Lago, E. et al. Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. *J Neurochem* **99**, 677-688 (2006).
510. Hamamoto, D. T., Giridharagopalan, S. & Simone, D. A. Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia. *Eur J Pharmacol S* (2006).
511. Russo, E. & Guy, G. W. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. *Med Hypotheses* **66**, 234-246 (2006).
512. Guzman, M. et al. A pilot clinical study of Delta(9)-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. *Br J Cancer* (2006).
513. Kogan, N. M. et al. A Cannabinoid Quinone Inhibits Angiogenesis by Targeting

- Vascular Endothelial Cells. *Mol Pharmacol* (2006).
514. Patsos, H. A. et al. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. *Gut* **54**, 1741-1750 (2005).
 515. Walsh, D., Kirkova, J. & Davis, M. P. The efficacy and tolerability of long-term use of dronabinol in cancer-related anorexia: a case series. *J Pain Symptom Manage* **30**, 493-495 (2005).
 516. Lombard, C., Nagarkatti, M. & Nagarkatti, P. S. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. *Leuk Res* **29**, 915-922 (2005).
 517. Sheng, W. S. et al. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. *Glia* **49**, 211-219 (2005).
 518. Tashkin, D. P. Smoked marijuana as a cause of lung injury. *Monaldi Arch Chest Dis* **63**, 93-100 (2005).
 519. Ramirez, B. G., Blazquez, C., Gomez del Pulgar, T., Guzman, M. & de Ceballos, M. L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. *J Neurosci* **25**, 1904-1913 (2005).
 520. Sarnataro, D. et al. Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. *FEBS Lett* **579**, 6343-6349 (2005).
 521. Sancho, R. et al. Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. *J Immunol* **175**, 3990-3999 (2005).
 522. Watanabe, K. et al. Marijuana extracts possess the effects like the endocrine disrupting chemicals. *Toxicology* **206**, 471-478 (2005).
 523. Sharma, R., Tobin, P. & Clarke, S. J. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. *Lancet Oncol* **6**, 93-102 (2005).
 524. Bari, M., Battista, N., Fezza, F., Finazzi-Agro, A. & Maccarrone, M. Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. *J Biol Chem* **280**, 12212-12220 (2005).
 525. Sun, Y. X. et al. Involvement of N-acyl ethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acyl ethanolamines in macrophages. *Biochim Biophys Acta* **1736**, 211-220 (2005).
 526. Kishimoto, S. et al. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. *J Biochem (Tokyo)* **137**, 217-223 (2005).
 527. Frider, E., Bregman, T. & Kirkham, T. C. Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. *Exp Biol Med (Maywood)* **230**, 225-234 (2005).
 528. Radbruch, L. & Elsner, F. Emerging analgesics in cancer pain management. *Expert Opin Emerg Drugs* **10**, 151-171 (2005).
 529. Guzman, M. Effects on cell viability. *Handb Exp Pharmacol* 627-642 (2005).
 530. Chung, K. F. Drugs to suppress cough. *Expert Opin Investig Drugs* **14**, 19-27 (2005).
 531. McKallip, R. J., Nagarkatti, M. & Nagarkatti, P. S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor

- immune response. *J Immunol* **174**, 3281-3289 (2005).
532. Bari, M., Paradisi, A., Pasquariello, N. & Maccarrone, M. Cholesterol-dependent modulation of type 1 cannabinoid receptors in nerve cells. *J Neurosci Res* **81**, 275-283 (2005).
533. Powles, T. et al. Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. *Blood* **105**, 1214-1221 (2005).
534. Melamede, R. Cannabis and tobacco smoke are not equally carcinogenic. *Harm Reduct J* **2**, 21 (2005).
535. McAllister, S. D. et al. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. *J Neurooncol* **74**, 31-40 (2005).
536. Ellert-Miklaszewska, A., Kaminska, B. & Konarska, L. Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. *Cell Signal* **17**, 25-37 (2005).
537. Izzo, A. A. & Coutts, A. A. Cannabinoids and the digestive tract. *Handb Exp Pharmacol* 573-598 (2005).
538. Patsos, H. A., Hicks, D. J., Greenhough, A., Williams, A. C. & Paraskeva, C. Cannabinoids and cancer: potential for colorectal cancer therapy. *Biochem Soc Trans* **33**, 712-714 (2005).
539. Hall, W., Christie, M. & Currow, D. Cannabinoids and cancer: causation, remediation, and palliation. *Lancet Oncol* **6**, 35-42 (2005).
540. Kogan, N. M. Cannabinoids and cancer. *Mini Rev Med Chem* **5**, 941-952 (2005).
541. Klein, T. W. Cannabinoid-based drugs as anti-inflammatory therapeutics. *Nat Rev Immunol* **5**, 400-411 (2005).
542. Flygare, J., Gustafsson, K., Kimby, E., Christensson, B. & Sander, B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. *FEBS Lett* **579**, 6885-6889 (2005).
543. Vaccani, A., Massi, P., Colombo, A., Rubino, T. & Parolaro, D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. *Br J Pharmacol* **144**, 1032-1036 (2005).
544. Myrianthefs, P. M. & Batistaki, C. Cancer cachexia and immunomodulation. *J BUON* **10**, 181-188 (2005).
545. Lee, S. Y., Oh, S. M., Lee, S. K. & Chung, K. H. Antiestrogenic effects of marijuana smoke condensate and cannabinoid compounds. *Arch Pharm Res* **28**, 1365-1375 (2005).
546. Roila, F. et al. Antiemetics in children receiving chemotherapy. *Support Care Cancer* **13**, 129-131 (2005).
547. Burstein, S. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials. *AAPS J* **7**, E143-E148 (2005).
548. Ortega-Gutierrez, S. et al. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. *FASEB J* **19**, 1338-1340 (2005).
549. Nithipatikom, K. et al. A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. *Biochem Biophys Res Commun* **332**, 1028-1033 (2005).
550. Inui, A. [Pathogenesis and treatment of cancer anorexia-cachexia, with special emphasis on aged patients]. *Nippon Ronen Igakkai Zasshi* **41**, 460-467 (2004).

551. Duran, M., Laporte, J. R. & Capella, D. [News about therapeutic use of Cannabis and endocannabinoid system]. *Med Clin (Barc)* **122**, 390-398 (2004).
552. Desreumaux, P., Thuru, X. & Philippe, D. [Control of secretory diarrhea and colorectal cancer growth by cannabinoids in the gut]. *Gastroenterol Clin Biol* **28**, 97 (2004).
553. Derkinderen, P., Valjent, E., Darcel, F., Damier, P. & Girault, J. A. [Cannabis and cannabinoid receptors: from pathophysiology to therapeutic options]. *Rev Neurol (Paris)* **160**, 639-649 (2004).
554. Rukwied, R., Gauter, B., Schley, M. & Konrad, C. [Cannabinoids-signal transduction and mode of action.]. *Schmerz* (2004).
555. Kraft, B. & Kress, H. G. [Cannabinoids and the immune system. Of men, mice and cells]. *Schmerz* **18**, 203-210 (2004).
556. Liang, Y. C., Huang, C. C. & Hsu, K. S. Therapeutic potential of cannabinoids in trigeminal neuralgia. *Curr Drug Targets CNS Neurol Disord* **3**, 507-514 (2004).
557. Rubovitch, V., Gafni, M. & Sarne, Y. The involvement of VEGF receptors and MAPK in the cannabinoid potentiation of Ca²⁺ flux into N18TG2 neuroblastoma cells. *Brain Res Mol Brain Res* **120**, 138-144 (2004).
558. Carlini, E. A. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans. *Toxicol* **44**, 461-467 (2004).
559. Coutts, A. A. & Izzo, A. A. The gastrointestinal pharmacology of cannabinoids: an update. *Curr Opin Pharmacol* **4**, 572-579 (2004).
560. Juttler, E. et al. The cannabinoid dexamabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B). *Neuropharmacology* **47**, 580-592 (2004).
561. Kogan, N. M. et al. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. *J Med Chem* **47**, 3800-3806 (2004).
562. Fowler, C. J., Tiger, G., Ligresti, A., Lopez-Rodriguez, M. L. & Di Marzo, V. Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle. *Eur J Pharmacol* **492**, 1-11 (2004).
563. Karlsson, M., Pahlsson, C. & Fowler, C. J. Reversible, temperature-dependent, and AM404-inhibitable adsorption of anandamide to cell culture wells as a confounding factor in release experiments. *Eur J Pharm Sci* **22**, 181-189 (2004).
564. Hinz, B., Ramer, R., Eichele, K., Weinzierl, U. & Brune, K. R(+)-methanandamide-induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. *Biochem Biophys Res Commun* **324**, 621-626 (2004).
565. Matias, I. et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. *J Pharmacol Exp Ther* **309**, 745-757 (2004).
566. Leggett, J. D. et al. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. *Br J Pharmacol* **141**, 253-262 (2004).
567. Carter, G. T., Weydt, P., Kyashna-Tocha, M. & Abrams, D. I. Medicinal cannabis: rational guidelines for dosing. *IDrugs* **7**, 464-470 (2004).
568. Carter, G. T. & Ugalde, V. Medical marijuana: emerging applications for the management of neurologic disorders. *Phys Med Rehabil Clin N Am* **15**, 943-54, ix (2004).
569. Martin, B. R. & Wiley, J. L. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. *J Support Oncol* **2**, 305-14; discussion

- 314 (2004).
570. Holt, S. et al. Lipopolysaccharide-induced pulmonary inflammation is not accompanied by a release of anandamide into the lavage fluid or a down-regulation of the activity of fatty acid amide hydrolase. *Life Sci* **76**, 461-472 (2004).
 571. Velasco, G., Galve-Roperh, I., Sanchez, C., Blazquez, C. & Guzman, M. Hypothesis: cannabinoid therapy for the treatment of gliomas? *Neuropharmacology* **47**, 315-323 (2004).
 572. Gertsch, J., Schoop, R., Kuenzle, U. & Suter, A. Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. *FEBS Lett* **577**, 563-569 (2004).
 573. Medveczky, M. M., Sherwood, T. A., Klein, T. W., Friedman, H. & Medveczky, P. G. Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro. *BMC Med* **2**, 34 (2004).
 574. Beale, R. C. et al. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. *J Mol Biol* **337**, 585-596 (2004).
 575. Carracedo, A. et al. Ceramide sensitizes astrocytes to oxidative stress: protective role of cannabinoids. *Biochem J* **380**, 435-440 (2004).
 576. Blazquez, C. et al. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. *Cancer Res* **64**, 5617-5623 (2004).
 577. Hart, S., Fischer, O. M. & Ullrich, A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. *Cancer Res* **64**, 1943-1950 (2004).
 578. Nauck, F. & Klaschik, E. Cannabinoids in the treatment of the cachexia-anorexia syndrome in palliative care patients. *Schmerz* **18**, 197-202 (2004).
 579. Cabral, G. A. & Marciano-Cabral, F. Cannabinoid-mediated exacerbation of brain infection by opportunistic amoebae. *J Neuroimmunol* **147**, 127-130 (2004).
 580. Contassot, E. et al. Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. *J Neuropathol Exp Neurol* **63**, 956-963 (2004).
 581. Contassot, E., Tenan, M., Schnuriger, V., Pelte, M. F. & Dietrich, P. Y. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. *Gynecol Oncol* **93**, 182-188 (2004).
 582. Massi, P. et al. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. *J Pharmacol Exp Ther* **308**, 838-845 (2004).
 583. Joseph, J., Niggemann, B., Zaenker, K. S. & Entschladen, F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. *Cancer Immunol Immunother* **53**, 723-728 (2004).
 584. Kalant, H. Adverse effects of cannabis on health: an update of the literature since 1996. *Prog Neuropsychopharmacol Biol Psychiatry* **28**, 849-863 (2004).
 585. Bifulco, M. et al. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. *FASEB J* **18**, 1606-1608 (2004).
 586. Bifulco, M. & Di Marzo, V. [The endocannabinoid system as a target for the development of new drugs for cancer therapy]. *Recenti Prog Med* **94**, 194-198 (2003).
 587. Radbruch, L. & Nauck, F. [A review of side effects and complications with

- cannabinoid treatment]. *Schmerz* **17**, 274-279 (2003).
588. Croxford, J. L. Therapeutic potential of cannabinoids in CNS disease. *CNS Drugs* **17**, 179-202 (2003).
589. Bash, R., Rubovitch, V., Gafni, M. & Sarne, Y. The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation. *Neurosignals* **12**, 39-44 (2003).
590. Maccarrone, M. et al. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. *J Biol Chem* **278**, 33896-33903 (2003).
591. Gilgun-Sherki, Y., Melamed, E., Mechoulam, R. & Offen, D. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. *Pharmacol Toxicol* **93**, 66-70 (2003).
592. Klein, T. W. et al. The cannabinoid system and immune modulation. *J Leukoc Biol* **74**, 486-496 (2003).
593. Trembovler, V., Abu-Raya, S. & Shohami, E. Synergism between tumor necrosis factor-alpha and H2O2 enhances cell damage in rat PC12 cells. *Neurosci Lett* **353**, 115-118 (2003).
594. Zurier, R. B., Rossetti, R. G., Burstein, S. H. & Bidinger, B. Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid. *Biochem Pharmacol* **65**, 649-655 (2003).
595. Croci, T., Landi, M., Galzin, A. M. & Marini, P. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. *Br J Pharmacol* **140**, 115-122 (2003).
596. Klegeris, A., Bissonnette, C. J. & McGeer, P. L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. *Br J Pharmacol* **139**, 775-786 (2003).
597. Wroblewski, S. T. et al. Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. *J Med Chem* **46**, 2110-2116 (2003).
598. Ligresti, A. et al. Possible endocannabinoid control of colorectal cancer growth. *Gastroenterology* **125**, 677-687 (2003).
599. Reggio, P. H. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors. *Curr Pharm Des* **9**, 1607-1633 (2003).
600. Grotenhermen, F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokinet* **42**, 327-360 (2003).
601. New toke on treating skin cancer. *Lab Anim (NY)* **32**, 12 (2003).
602. Vandevoorde, S., Lambert, D. M., Smart, D., Jonsson, K. O. & Fowler, C. J. N-Morpholino- and N-diethyl-analogues of palmitoylethanolamide increase the sensitivity of transfected human vanilloid receptors to activation by anandamide without affecting fatty acid amidohydrolase activity. *Bioorg Med Chem* **11**, 817-825 (2003).
603. Keren, O. & Sarne, Y. Multiple mechanisms of CB1 cannabinoid receptors regulation. *Brain Res* **980**, 197-205 (2003).
604. Gardner, B., Zhu, L. X., Sharma, S., Tashkin, D. P. & Dubinett, S. M. Methanandamide increases COX-2 expression and tumor growth in murine lung

- cancer. *FASEB J* **17**, 2157-2159 (2003).
605. Portella, G. et al. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. *FASEB J* **17**, 1771-1773 (2003).
606. Blazquez, C. et al. Inhibition of tumor angiogenesis by cannabinoids. *FASEB J* **17**, 529-531 (2003).
607. Casanova, M. L. et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. *J Clin Invest* **111**, 43-50 (2003).
608. Ihenetu, K., Molleman, A., Parsons, M. E. & Whelan, C. J. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. *Eur J Pharmacol* **458**, 207-215 (2003).
609. Fowler, C. J. et al. Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid. *Biochem Pharmacol* **66**, 757-767 (2003).
610. Hinz, B., Ramer, R. & Brune, K. Induction of COX-2 expression by the endocannabinoid derivative R(+)-methanandamide. *Adv Exp Med Biol* **525**, 145-152 (2003).
611. Grotenhermen, F. & Muller-Vahl, K. IACM 2nd Conference on Cannabinoids in Medicine. *Expert Opin Pharmacother* **4**, 2367-2371 (2003).
612. Gallily, R. et al. gamma-Irradiation Enhances Apoptosis Induced by Cannabidiol, a Non-psychotropic Cannabinoid, in Cultured HL-60 Myeloblastic Leukemia Cells. *Leuk Lymphoma* **44**, 1767-1773 (2003).
613. Glaser, S. T. et al. Evidence against the presence of an anandamide transporter. *Proc Natl Acad Sci U S A* **100**, 4269-4274 (2003).
614. Walsh, D., Nelson, K. A. & Mahmoud, F. A. Established and potential therapeutic applications of cannabinoids in oncology. *Support Care Cancer* **11**, 137-143 (2003).
615. Sanchez, M. G., Sanchez, A. M., Ruiz-Llorente, L. & Diaz-Laviada, I. Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. *FEBS Lett* **555**, 561-566 (2003).
616. Parker, L. A. et al. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. *Psychopharmacology (Berl)* **166**, 156-162 (2003).
617. Samson, M. T. et al. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. *J Immunol* **170**, 4953-4962 (2003).
618. Dexanabinol: dexanabinone, HU 211, PA 50211, PRS 211007, sinnabidol. *Drugs R D* **4**, 185-187 (2003).
619. Tarzia, G. et al. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. *J Med Chem* **46**, 2352-2360 (2003).
620. Sarafian, T. et al. Clarifying Cb2 Receptor-dependent and Independent Effects of Thec on Human Lung Epithelial Cells. *Toxicol Appl Pharmacol* (2008).
621. Ramer, R., Weinzierl, U., Schwind, B., Brune, K. & Hinz, B. Ceramide is involved in r(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. *Mol Pharmacol* **64**, 1189-1198 (2003).
622. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD. *Drugs R D* **4**, 306-309 (2003).

623. Ware, M. A., Doyle, C. R., Woods, R., Lynch, M. E. & Clark, A. J. Cannabis use for chronic non-cancer pain: results of a prospective survey. *Pain* **102**, 211-216 (2003).
624. Guzman, M. Cannabinoids: potential anticancer agents. *Nat Rev Cancer* **3**, 745-755 (2003).
625. Upham, B. L. et al. Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line. *Int J Cancer* **104**, 12-18 (2003).
626. Bruera, E. & Castro, M. Cannabinoids in supportive care: are they necessary? *Support Care Cancer* **11**, 133-134 (2003).
627. Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M. & Leon, A. Cannabinoids ablate release of TNF α in rat microglial cells stimulated with lipopolysaccharide. *Glia* **41**, 161-168 (2003).
628. Vannacci, A., Giannini, L., Masini, E. & Mannaioni, P. F. Cannabinoid-induced activation of ERK and AKT in mast cells may be mediated by intracellular NO production. *J Immunol* **171**, 2767 (2003).
629. Toth, A., Kedei, N., Wang, Y. & Blumberg, P. M. Arachidonyl dopamine as a ligand for the vanilloid receptor VR1 of the rat. *Life Sci* **73**, 487-498 (2003).
630. Kingsley, P. J. & Marnett, L. J. Analysis of endocannabinoids by Ag⁺ coordination tandem mass spectrometry. *Anal Biochem* **314**, 8-15 (2003).
631. Kozak, K. R., Prusakiewicz, J. J., Rowlinson, S. W., Prudhomme, D. R. & Marnett, L. J. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid anandamide. *Biochemistry* **42**, 9041-9049 (2003).
632. Jonsson, K. O. et al. AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide. *Arch Toxicol* **77**, 201-207 (2003).
633. Sanchez, M. G., Ruiz-Llorente, L., Sanchez, A. M. & Diaz-Laviada, I. Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. *Cell Signal* **15**, 851-859 (2003).
634. Davis, M. I., Ronesi, J. & Lovinger, D. M. A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells. *J Biol Chem* **278**, 48973-48980 (2003).
635. Lavon, I. et al. A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation. *Mol Pharmacol* **64**, 1334-1341 (2003).
636. Kehl, L. J. et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. *Pain* **103**, 175-186 (2003).
637. Ockenga, J., Pirlich, M., Gastell, S. & Lochs, H. [Tumour anorexia--tumour cachexia in case of gastrointestinal tumours: standards and visions]. *Z Gastroenterol* **40**, 929-936 (2002).
638. Zurcher, G. [Anorectic syndrome]. *Z Gastroenterol* **40 Suppl 1**, S71-SS5 (2002).
639. Esposito, G. et al. The endocannabinoid system protects rat glioma cells against HIV-1 Tat protein-induced cytotoxicity. Mechanism and regulation. *J Biol Chem* **277**, 50348-50354 (2002).
640. Hinnebusch, B. F., Meng, S., Wu, J. T., Archer, S. Y. & Hodin, R. A. The effects of

- short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. *J Nutr* **132**, 1012-1017 (2002).
641. Rubovitch, V., Gafni, M. & Sarne, Y. The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. *Brain Res Mol Brain Res* **101**, 93-102 (2002).
 642. Bifulco, M. & Di Marzo, V. Targeting the endocannabinoid system in cancer therapy: a call for further research. *Nat Med* **8**, 547-550 (2002).
 643. McKallip, R. J. et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. *Blood* **100**, 627-634 (2002).
 644. Sarafian, T. A., Kouyoumjian, S., Tashkin, D. & Roth, M. D. Synergistic cytotoxicity of Delta(9)-tetrahydrocannabinol and butylated hydroxyanisole. *Toxicol Lett* **133**, 171-179 (2002).
 645. Tashkin, D. P., Baldwin, G. C., Sarafian, T., Dubinett, S. & Roth, M. D. Respiratory and immunologic consequences of marijuana smoking. *J Clin Pharmacol* **42**, 71S-81S (2002).
 646. van der Stelt, M. et al. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. *J Med Chem* **45**, 3709-3720 (2002).
 647. Kozak, K. R. & Marnett, L. J. Oxidative metabolism of endocannabinoids. *Prostaglandins Leukot Essent Fatty Acids* **66**, 211-220 (2002).
 648. Kozak, K. R. Metabolism of the endocannabinoids, 2-arachidonoylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. *J Biol Chem* **277**, 44877-44885 (2002).
 649. Kozak, K. R. et al. Metabolism of the endocannabinoids, 2-arachidonoylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. *J Biol Chem* **277**, 44877-44885 (2002).
 650. Galve-Roperh, I., Rueda, D., Gomez del Pulgar, T., Velasco, G. & Guzman, M. Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. *Mol Pharmacol* **62**, 1385-1392 (2002).
 651. Hashibe, M., Ford, D. E. & Zhang, Z. F. Marijuana smoking and head and neck cancer. *J Clin Pharmacol* **42**, 103S-107S (2002).
 652. Ek, S., Hogerkorp, C. M., Dictor, M., Ehinger, M. & Borrebaeck, C. A. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. *Cancer Res* **62**, 4398-4405 (2002).
 653. Parolaro, D., Massi, P., Rubino, T. & Monti, E. Endocannabinoids in the immune system and cancer. *Prostaglandins Leukot Essent Fatty Acids* **66**, 319-332 (2002).
 654. Fernandez-Ruiz, J., Lastres-Becker, I., Cabranes, A., Gonzalez, S. & Ramos, J. A. Endocannabinoids and basal ganglia functionality. *Prostaglandins Leukot Essent Fatty Acids* **66**, 257-267 (2002).
 655. De Petrocellis, L. et al. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. *Fundam Clin Pharmacol* **16**, 297-302 (2002).
 656. Germain, N., Boichot, E., Advenier, C., Berdyshev, E. V. & Lagente, V. Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-

- alpha production by human mononuclear cells. *Int Immunopharmacol* **2**, 537-543 (2002).
657. Jatoi, A. et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. *J Clin Oncol* **20**, 567-573 (2002).
658. Jatoi, A. et al. Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. *Support Care Cancer* **10**, 71-75 (2002).
659. Gomez del Pulgar, T., Velasco, G., Sanchez, C., Haro, A. & Guzman, M. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. *Biochem J* **363**, 183-188 (2002).
660. Zhou, D. & Song, Z. H. CB1 cannabinoid receptor-mediated tyrosine phosphorylation of focal adhesion kinase-related non-kinase. *FEBS Lett* **525**, 164-168 (2002).
661. Carter, G. T. & Weydt, P. Cannabis: old medicine with new promise for neurological disorders. *Curr Opin Investig Drugs* **3**, 437-440 (2002).
662. Gomez Del Pulgar, T., De Ceballos, M. L., Guzman, M. & Velasco, G. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. *J Biol Chem* **277**, 36527-36533 (2002).
663. Smith, P. F. Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. *Curr Opin Investig Drugs* **3**, 859-864 (2002).
664. Pertwee, R. G. & Ross, R. A. Cannabinoid receptors and their ligands. *Prostaglandins Leukot Essent Fatty Acids* **66**, 101-121 (2002).
665. Melck, D. et al. Cannabimimetic eicosanoids in cancer and inflammation: an update. *Adv Exp Med Biol* **507**, 381-386 (2002).
666. Inui, A. Cancer anorexia-cachexia syndrome: current issues in research and management. *CA Cancer J Clin* **52**, 72-91 (2002).
667. Maccarrone, M., Pauselli, R., Di Rienzo, M. & Finazzi-Agro, A. Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. *Biochem J* **366**, 137-144 (2002).
668. Ishii, I. & Chun, J. Anandamide-induced neuroblastoma cell rounding via the CB1 cannabinoid receptors. *Neuroreport* **13**, 593-596 (2002).
669. Bisogno, T. et al. The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. *Eur J Biochem* **268**, 1982-1989 (2001).
670. Mechoulam, R. & Hanu, L. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. *Pain Res Manag* **6**, 67-73 (2001).
671. Ripamonti, C. & Dickerson, E. D. Strategies for the treatment of cancer pain in the new millennium. *Drugs* **61**, 955-977 (2001).
672. Moody, J. S., Kozak, K. R., Ji, C. & Marnett, L. J. Selective oxygenation of the endocannabinoid 2-arachidonoylglycerol by leukocyte-type 12-lipoxygenase. *Biochemistry* **40**, 861-866 (2001).
673. Esposito, G., Izzo, A. A., Di Rosa, M. & Iuvone, T. Selective cannabinoid CB1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in

- C6 rat glioma cells. *J Neurochem* **78**, 835-841 (2001).
674. Day, T. A., Rakhshan, F., Deutsch, D. G. & Barker, E. L. Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. *Mol Pharmacol* **59**, 1369-1375 (2001).
675. Ramer, R., Brune, K., Pahl, A. & Hinz, B. R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism. *Biochem Biophys Res Commun* **286**, 1144-1152 (2001).
676. Di Marzo, V. et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. *Biochem J* **358**, 249-255 (2001).
677. Pagotto, U. et al. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. *J Clin Endocrinol Metab* **86**, 2687-2696 (2001).
678. Smith, S. R., Terminelli, C. & Denhardt, G. Modulation of cytokine responses in *Corynebacterium parvum*-primed endotoxemic mice by centrally administered cannabinoid ligands. *Eur J Pharmacol* **425**, 73-83 (2001).
679. Kalant, H. Medicinal use of cannabis: history and current status. *Pain Res Manag* **6**, 80-91 (2001).
680. Sarafian, T. A., Tashkin, D. P. & Roth, M. D. Marijuana smoke and Delta(9)-tetrahydrocannabinol promote necrotic cell death but inhibit Fas-mediated apoptosis. *Toxicol Appl Pharmacol* **174**, 264-272 (2001).
681. Jacobsson, S. O., Wallin, T. & Fowler, C. J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. *J Pharmacol Exp Ther* **299**, 951-959 (2001).
682. Sanchez, C. et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. *Cancer Res* **61**, 5784-5789 (2001).
683. Roth, M. D. et al. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. *Am J Respir Cell Mol Biol* **24**, 339-344 (2001).
684. Maccarrone, M., Attina, M., Cartoni, A., Bari, M. & Finazzi-Agro, A. Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. *J Neurochem* **76**, 594-601 (2001).
685. Jonsson, K. O., Vandevoorde, S., Lambert, D. M., Tiger, G. & Fowler, C. J. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. *Br J Pharmacol* **133**, 1263-1275 (2001).
686. ElSohly, M. A., deWit, H., Wachtel, S. R., Feng, S. & Murphy, T. P. Delta9-tetrahydrocannabinol as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. *J Anal Toxicol* **25**, 565-571 (2001).
687. Velasco, L., Ruiz, L., Sanchez, M. G. & Diaz-Laviada, I. delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1. *Eur J Biochem* **268**, 531-535 (2001).
688. Darmani, N. A. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent

- emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. *Neuropsychopharmacology* **24**, 198-203 (2001).
689. Guzman, M., Sanchez, C. & Galve-Roperh, I. Control of the cell survival/death decision by cannabinoids. *J Mol Med* **78**, 613-625 (2001).
690. Bifulco, M. et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. *FASEB J* **15**, 2745-2747 (2001).
691. Jacobsson, S. O. & Fowler, C. J. Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. *Br J Pharmacol* **132**, 1743-1754 (2001).
692. Zhou, D. & Song, Z. H. CB1 cannabinoid receptor-mediated neurite remodeling in mouse neuroblastoma N1E-115 cells. *J Neurosci Res* **65**, 346-353 (2001).
693. Walker, J. M., Strangman, N. M. & Huang, S. M. Cannabinoids and pain. *Pain Res Manag* **6**, 74-79 (2001).
694. Campbell, F. A. et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. *BMJ* **323**, 13-16 (2001).
695. Recht, L. D. et al. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid. *Biochem Pharmacol* **62**, 755-763 (2001).
696. Jamshidi, N. & Taylor, D. A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. *Br J Pharmacol* **134**, 1151-1154 (2001).
697. Kozak, K. R., Prusakiewicz, J. J., Rowlinson, S. W., Schneider, C. & Marnett, L. J. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid 2-arachidonylethanolamide. *J Biol Chem* **276**, 30072-30077 (2001).
698. Tashkin, D. P. Airway effects of marijuana, cocaine, and other inhaled illicit agents. *Curr Opin Pulm Med* **7**, 43-61 (2001).
699. Lorenzo Fernandez, P. [Potential therapeutic usefulness of cannabis and cannabinoids]. *An R Acad Nac Med (Madr)* **117**, 595-605; discussion 616 (2000).
700. Carriot, F. & Sasso, A. J. [Cannabis and cancer]. *Rev Epidemiol Sante Publique* **48**, 473-483 (2000).
701. Benard, J. [Cannabinoids, among others, send malignant glial tumors to nirvana.]. *Bull Cancer* **87**, 299-300 (2000).
702. Malfait, A. M. et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. *Proc Natl Acad Sci U S A* **97**, 9561-9566 (2000).
703. Gomez del Pulgar, T., Velasco, G. & Guzman, M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. *Biochem J* **347**, 369-373 (2000).
704. Klein, T. W., Lane, B., Newton, C. A. & Friedman, H. The cannabinoid system and cytokine network. *Proc Soc Exp Biol Med* **225**, 1-8 (2000).
705. Han, D. S. et al. Synthesis and cytotoxic effects of deoxy-tomentellin. *Arch Pharm Res* **23**, 121-127 (2000).
706. Muthian, S., Nithipatikom, K., Campbell, W. B. & Hillard, C. J. Synthesis and characterization of a fluorescent substrate for the N-arachidonylethanolamine (anandamide) transmembrane carrier. *J Pharmacol Exp Ther* **293**, 289-295 (2000).
707. Melck, D. et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. *Endocrinology* **141**, 118-126 (2000).
708. Jacobsson, S. O., Rongard, E., Stridh, M., Tiger, G. & Fowler, C. J. Serum-

- dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. *Biochem Pharmacol* **60**, 1807-1813 (2000).
709. Yea, S. S., Yang, K. H. & Kaminski, N. E. Role of nuclear factor of activated T-cells and activator protein-1 in the inhibition of interleukin-2 gene transcription by cannabinol in EL4 T-cells. *J Pharmacol Exp Ther* **292**, 597-605 (2000).
710. Kosior, D. A., Filipiak, K. J., Stolarz, P. & Opolski, G. Paroxysmal atrial fibrillation in a young female patient following marijuana intoxication--a case report of possible association. *Med Sci Monit* **6**, 386-389 (2000).
711. De Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G. & Di Marzo, V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. *FEBS Lett* **483**, 52-56 (2000).
712. Molnar, J. et al. Membrane associated antitumor effects of crocine-, ginsenoside- and cannabinoid derivatives. *Anticancer Res* **20**, 861-867 (2000).
713. Di, M., Bisogno, T. & De Petrocellis, L. Endocannabinoids: new targets for drug development. *Curr Pharm Des* **6**, 1361-1380 (2000).
714. De Petrocellis, L., Melck, D., Bisogno, T. & Di Marzo, V. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. *Chem Phys Lipids* **108**, 191-209 (2000).
715. Smith, S. R., Terminelli, C. & Denhardt, G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. *J Pharmacol Exp Ther* **293**, 136-150 (2000).
716. MacCarrone, M. et al. Down-regulation of anandamide hydrolase in mouse uterus by sex hormones. *Eur J Biochem* **267**, 2991-2997 (2000).
717. Zhu, L. X. et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. *J Immunol* **165**, 373-380 (2000).
718. Kaferstein, H. & Sticht, G. Comparison of nonradioactive microtiter plate enzyme immunoassays for the sensitive detection of fentanyl. *Forensic Sci Int* **113**, 353-357 (2000).
719. Rubino, T. et al. Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. *Neuropharmacology* **39**, 1331-1336 (2000).
720. Puffenbarger, R. A., Boothe, A. C. & Cabral, G. A. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. *Glia* **29**, 58-69 (2000).
721. Ho, B. Y. et al. Cannabinoid CB1 receptor-mediated inhibition of prolactin release and signaling mechanisms in GH4C1 cells. *Endocrinology* **141**, 1675-1685 (2000).
722. Di Marzo, V., Melck, D., De Petrocellis, L. & Bisogno, T. Cannabimimetic fatty acid derivatives in cancer and inflammation. *Prostaglandins Other Lipid Mediat* **61**, 43-61 (2000).
723. Galve-Roperh, I. et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. *Nat Med* **6**, 313-319 (2000).
724. Maccarrone, M., Lorenzon, T., Bari, M., Melino, G. & Finazzi-Agro, A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for

- a protective role of cannabinoid receptors. *J Biol Chem* **275**, 31938-31945 (2000).
725. Maccarrone, M., Salvati, S., Bari, M. & Finazzi-Agro. Anandamide and 2-arachidonoylglycerol inhibit fatty acid amide hydrolase by activating the lipoxygenase pathway of the arachidonate cascade. *Biochem Biophys Res Commun* **278**, 576-583 (2000).
726. Gallily, R., Breuer, A. & Mechoulam, R. 2-Arachidonoylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. *Eur J Pharmacol* **406**, R5-R7 (2000).
727. Masset, D., Bourdon, J. H., Arditti-Djiane, J. & Jouglard, J. [Impact of delta-9-tetrahydrocannabinol and its metabolites on the immune system]. *Acta Clin Belg Suppl* **1**, 39-43 (1999).
728. Melck, D. et al. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. *Biochem Biophys Res Commun* **262**, 275-284 (1999).
729. listed], [N. A. Studies of high-dose chemotherapy with stem cell support for breast cancer. *Am J Health Syst Pharm* **56**, 940 (1999).
730. Valk, P. J. et al. Retroviral insertions in Evi12, a novel common virus integration site upstream of Tra1/Grp94, frequently coincide with insertions in the gene encoding the peripheral cannabinoid receptor Cnr2. *J Virol* **73**, 3595-3602 (1999).
731. Mukhopadhyay, S., Cowsik, S. M., Lynn, A. M., Welsh, W. J. & Howlett, A. C. Regulation of Gi by the CB1 cannabinoid receptor C-terminal juxtamembrane region: structural requirements determined by peptide analysis. *Biochemistry* **38**, 3447-3455 (1999).
732. Mechoulam, R. Recent advantages in cannabinoid research. *Forsch Komplementarmed* **6 Suppl 3**, 16-20 (1999).
733. Sarafian, T. A., Magallanes, J. A., Shau, H., Tashkin, D. & Roth, M. D. Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids. *Am J Respir Cell Mol Biol* **20**, 1286-1293 (1999).
734. Zhang, Z. F. et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. *Cancer Epidemiol Biomarkers Prev* **8**, 1071-1078 (1999).
735. Rosenthal, M. S. & Kleber, H. D. Making sense of medical marijuana. *Proc Assoc Am Physicians* **111**, 159-165 (1999).
736. Berglund, B. A., Boring, D. L. & Howlett, A. C. Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils. *Adv Exp Med Biol* **469**, 527-533 (1999).
737. Leker, R. R., Shohami, E., Abramsky, O. & Ovadia, H. Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. *J Neurol Sci* **162**, 114-119 (1999).
738. Ruiz, L., Miguel, A. & Diaz-Laviada, I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. *FEBS Lett* **458**, 400-404 (1999).
739. Basavarajappa, B. S. & Hungund, B. L. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells. *J Neurochem* **72**, 522-528 (1999).
740. Kenney, S. P. et al. Cannabinoid receptors and their role in the regulation of the

- serotonin transporter in human placenta. *Am J Obstet Gynecol* **181**, 491-497 (1999).
741. Gorter, R. W. Cancer cachexia and cannabinoids. *Forsch Komplementarmed* **6 Suppl 3**, 21-22 (1999).
 742. Lambert, D. M. et al. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. *Biochim Biophys Acta* **1440**, 266-274 (1999).
 743. Bruera, E. & Neumann, C. M. The uses of psychotropics in symptom management in advanced cancer. *Psychooncology* **7**, 346-358 (1998).
 744. Di Marzo, V., Bisogno, T., Sugiura, T., Melck, D. & De Petrocellis, L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. *Biochem J* **331**, 15-19 (1998).
 745. Derocq, J. M. et al. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. *FEBS Lett* **425**, 419-425 (1998).
 746. De Petrocellis, L. et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. *Proc Natl Acad Sci U S A* **95**, 8375-8380 (1998).
 747. Di Toro, R., Campana, G., Sciarretta, V., Murari, G. & Spampinato, S. Regulation of delta opioid receptors by delta9-tetrahydrocannabinol in NG108-15 hybrid cells. *Life Sci* **63**, PL197-PL204 (1998).
 748. Di Marzo, V. et al. Interactions between synthetic vanilloids and the endogenous cannabinoid system. *FEBS Lett* **436**, 449-454 (1998).
 749. Barsky, S. H., Roth, M. D., Klerup, E. C., Simmons, M. & Tashkin, D. P. Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. *J Natl Cancer Inst* **90**, 1198-1205 (1998).
 750. Zurier, R. B. et al. Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. *Arthritis Rheum* **41**, 163-170 (1998).
 751. Sanchez, C., Galve-Roperh, I., Canova, C., Brachet, P. & Guzman, M. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. *FEBS Lett* **436**, 6-10 (1998).
 752. Srivastava, M. D., Srivastava, B. I. & Brouhard, B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. *Immunopharmacology* **40**, 179-185 (1998).
 753. Herrstedt, J., Aapro, M. S., Smyth, J. F. & Del Favero, A. Corticosteroids, dopamine antagonists and other drugs. *Support Care Cancer* **6**, 204-214 (1998).
 754. Ongradi, J., Specter, S., Horvath, A. & Friedman, H. Combined in vitro effect of marijuana and retrovirus on the activity of mouse natural killer cells. *Pathol Oncol Res* **4**, 191-199 (1998).
 755. Baek, S. H. et al. Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. *Arch Pharm Res* **21**, 353-356 (1998).
 756. Bisogno, T. et al. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells--implications for cell proliferation and differentiation. *Eur J Biochem* **254**, 634-642 (1998).
 757. Bisogno, T. et al. Arachidonoylserotonin and other novel inhibitors of fatty acid

- amide hydrolase. *Biochem Biophys Res Commun* **248**, 515-522 (1998).
758. Maccarrone, M. et al. Anandamide hydrolysis by human cells in culture and brain. *J Biol Chem* **273**, 32332-32339 (1998).
759. Taylor, H. G. Analysis of the medical use of marijuana and its societal implications. *J Am Pharm Assoc (Wash)* **38**, 220-227 (1998).
760. Roth, M. D. et al. Airway inflammation in young marijuana and tobacco smokers. *Am J Respir Crit Care Med* **157**, 928-937 (1998).
761. Calhoun, S. R., Galloway, G. P. & Smith, D. E. Abuse potential of dronabinol (Marinol). *J Psychoactive Drugs* **30**, 187-196 (1998).
762. Bisogno, T., Sepe, N., De Petrocellis, L., Mechoulam, R. & Di Marzo, V. The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. *Biochem Biophys Res Commun* **239**, 473-479 (1997).
763. Goodman, M. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting. *Oncol Nurs Forum* **24**, 20-32 (1997).
764. Hunter, S. A. & Burstein, S. H. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. *Life Sci* **60**, 1563-1573 (1997).
765. Gallily, R. et al. Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexamabinol (HU-211), a nonpsychotropic cannabinoid. *J Pharmacol Exp Ther* **283**, 918-924 (1997).
766. Voth, E. A. & Schwartz, R. H. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. *Ann Intern Med* **126**, 791-798 (1997).
767. McPartland, J. M. & Pruitt, P. L. Medical marijuana and its use by the immunocompromised. *Altern Ther Health Med* **3**, 39-45 (1997).
768. Baldwin, G. C. et al. Marijuana and cocaine impair alveolar macrophage function and cytokine production. *Am J Respir Crit Care Med* **156**, 1606-1613 (1997).
769. Abood, M. E., Ditto, K. E., Noel, M. A., Showalter, V. M. & Tao, Q. Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells. *Biochem Pharmacol* **53**, 207-214 (1997).
770. Gonzalez-Rosales, F. & Walsh, D. Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (dronabinol). *J Pain Symptom Manage* **14**, 311-314 (1997).
771. Berdyshev, E. V. et al. Influence of fatty acid ethanolamides and delta-9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. *Eur J Pharmacol* **330**, 231-240 (1997).
772. Deutsch, D. G. et al. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. *Biochem Biophys Res Commun* **231**, 217-221 (1997).
773. Ruh, M. F., Taylor, J. A., Howlett, A. C. & Welshons, W. V. Failure of cannabinoid compounds to stimulate estrogen receptors. *Biochem Pharmacol* **53**, 35-41 (1997).
774. Sanchez, C., Velasco, G. & Guzman, M. Delta-9-tetrahydrocannabinol stimulates glucose utilization in C6 glioma cells. *Brain Res* **767**, 64-71 (1997).
775. Shohami, E., Gallily, R., Mechoulam, R., Bass, R. & Ben-Hur, T. Cytokine production in the brain following closed head injury: dexamabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. *J Neuroimmunol* **72**,

- 169-177 (1997).
776. Schatz, A. R., Lee, M., Condie, R. B., Pulaski, J. T. & Kaminski, N. E. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. *Toxicol Appl Pharmacol* **142**, 278-287 (1997).
777. De Petrocellis, L. et al. Brain and peripheral anandamide amidohydrolase and its inhibition by synthetic arachidonate analogues. *Adv Exp Med Biol* **433**, 259-263 (1997).
778. Bisogno, T. et al. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. *Biochem J* **322**, 671-677 (1997).
779. Axelrod, R. S. Antiemetic therapy. *Compr Ther* **23**, 539-545 (1997).
780. Molina-Holgado, F., Lledo, A. & Guaza, C. Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. *Neuroreport* **8**, 1929-1933 (1997).
781. Chan, P. C., Sills, R. C., Braun, A. G., Haseman, J. K. & Bucher, J. R. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. *Fundam Appl Toxicol* **30**, 109-117 (1996).
782. Lew, G. M. Tau protein after delta-9-tetrahydrocannabinol in a human neuroblastoma cell line. *Gen Pharmacol* **27**, 1141-1143 (1996).
783. Di Marzo, V., De Petrocellis, L., Sugiura, T. & Waku, K. Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells. *Biochem Biophys Res Commun* **227**, 281-288 (1996).
784. NIH. NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)-Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies). *Natl Toxicol Program Tech Rep Ser S* **446**, 1-317 (1996).
785. Abood, M. E. & Martin, B. R. Molecular neurobiology of the cannabinoid receptor. *Int Rev Neurobiol* **39**, 197-221 (1996).
786. Ho, B. Y. & Zhao, J. Determination of the cannabinoid receptors in mouse x rat hybridoma NG108-15 cells and rat GH4C1 cells. *Neurosci Lett* **212**, 123-126 (1996).
787. Zheng, Z. M. & Specter, S. C. Delta-9-tetrahydrocannabinol suppresses tumor necrosis factor alpha maturation and secretion but not its transcription in mouse macrophages. *Int J Immunopharmacol* **18**, 53-68 (1996).
788. Bhargava, H. N., House, R. V., Thorat, S. N. & Thomas, P. T. Cellular immune function in mice tolerant to or abstinent from l-trans-delta 9-tetrahydrocannabinol. *Pharmacology* **52**, 271-282 (1996).
789. Di Marzo, V., De Petrocellis, L., Sepe, N. & Buono, A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. *Biochem J* **316**, 977-984 (1996).
790. Bass, R., Engelhard, D., Trembovler, V. & Shohami, E. A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis. *J Infect Dis* **173**, 735-738 (1996).
791. Burstein, S. H. & Hunter, S. A. Stimulation of anandamide biosynthesis in N-18TG2 neuroblastoma cells by delta 9-tetrahydrocannabinol (THC). *Biochem*

- Pharmacol* **49**, 855-858 (1995).
792. Gilbert, C. J., Ohly, K. V., Rosner, G. & Peters, W. P. Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. *Cancer* **76**, 2330-2337 (1995).
793. Smart, T. Other therapies for wasting. *GMHC Treat Issues* **9(5)**, 7-8, 12 (1995).
794. Frider, E. et al. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol. *J Pharmacol Exp Ther* **272**, 699-707 (1995).
795. Gibertini, M., Newton, C., Friedman, H. & Klein, T. W. IL-1 beta and TNF alpha modulate delta 9-tetrahydrocannabinol-induced catalepsy in mice. *Pharmacol Biochem Behav* **50**, 141-146 (1995).
796. Hirst, R. A. & Lambert, D. G. Do SH-SY5Y human neuroblastoma cells express cannabinoid receptors? *Biochem Soc Trans* **23**, 418S (1995).
797. Burnette-Curley, D. & Cabral, G. A. Differential inhibition of RAW264.7 macrophage tumoricidal activity by delta 9-tetrahydrocannabinol. *Proc Soc Exp Biol Med* **210**, 64-76 (1995).
798. Klein, T. W., Newton, C., Zhu, W., Daaka, Y. & Friedman, H. delta 9-Tetrahydrocannabinol, cytokines, and immunity to *Legionella pneumophila*. *Proc Soc Exp Biol Med* **209**, 205-212 (1995).
799. Mackie, K., Lai, Y., Westenbroek, R. & Mitchell, R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. *J Neurosci* **15**, 6552-6561 (1995).
800. Cabral, G. A., Toney, D. M., Fischer-Stenger, K., Harrison, M. P. & Marciano-Cabral, F. Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. *Life Sci* **56**, 2065-2072 (1995).
801. Zheng, Z. M. & Specter, S. Suppression by delta-9-tetrahydrocannabinol of lipopolysaccharide-induced and intrinsic tyrosine phosphorylation and protein expression in mouse peritoneal macrophages. *Biochem Pharmacol* **47**, 2243-2252 (1994).
802. Koutek, B. et al. Inhibitors of arachidonoyl ethanolamide hydrolysis. *J Biol Chem* **269**, 22937-22940 (1994).
803. Cabral, G. A. & Fischer-Stenger, K. Inhibition of macrophage inducible protein expression by delta-9-tetrahydrocannabinol. *Life Sci* **54**, 1831-1844 (1994).
804. Kusher, D. I., Dawson, L. O., Taylor, A. C. & Djeu, J. Y. Effect of the psychoactive metabolite of marijuana, delta 9-tetrahydrocannabinol (THC), on the synthesis of tumor necrosis factor by human large granular lymphocytes. *Cell Immunol* **154**, 99-108 (1994).
805. Trisler, K. & Specter, S. Delta-9-tetrahydrocannabinol treatment results in a suppression of interleukin-2-induced cellular activities in human and murine lymphocytes. *Int J Immunopharmacol* **16**, 593-603 (1994).
806. Shivers, S. C., Newton, C., Friedman, H. & Klein, T. W. delta 9-Tetrahydrocannabinol (THC) modulates IL-1 bioactivity in human monocyte/macrophage cell lines. *Life Sci* **54**, 1281-1289 (1994).
807. Vigano, A., Watanabe, S. & Bruera, E. Anorexia and cachexia in advanced cancer patients. *Cancer Surv* **21**, 99-115 (1994).

808. Nelson, K., Walsh, D., Deeter, P. & Sheehan, F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. *J Palliat Care* **10**, 14-18 (1994).
809. Melvin, L. S. et al. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. *Mol Pharmacol* **44**, 1008-1015 (1993).
810. Zheng, Z. M., Specter, S. & Friedman, H. Serum proteins affect the inhibition by delta-tetrahydrocannabinol of tumor necrosis factor alpha production by mouse macrophages. *Adv Exp Med Biol* **335**, 89-93 (1993).
811. Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular Characterization of a Peripheral Receptor for Cannabinoids. *Nature* **365**, 61-65 (1993).
812. Bruera, E. Is the pharmacological treatment of cancer cachexia possible? *Support Care Cancer* **1**, 298-304 (1993).
813. Burnette-Curley, D., Marciano-Cabral, F., Fischer-Stenger, K. & Cabral, G. A. delta-9-Tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmette-Guerin-activated macrophages. *Int J Immunopharmacol* **15**, 371-382 (1993).
814. Klein, T. W., Newton, C., Widen, R. & Friedman, H. Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. *J Pharmacol Exp Ther* **267**, 635-640 (1993).
815. Fischer-Stenger, K., Dove Pettit, D. A. & Cabral, G. A. Delta 9-tetrahydrocannabinol inhibition of tumor necrosis factor-alpha: suppression of post-translational events. *J Pharmacol Exp Ther* **267**, 1558-1565 (1993).
816. Bouaboula, M. et al. Cannabinoid-receptor expression in human leukocytes. *Eur J Biochem* **214**, 173-180 (1993).
817. Mackie, K., Devane, W. A. & Hille, B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. *Mol Pharmacol* **44**, 498-503 (1993).
818. Nahas, G. & Latour, C. The human toxicity of marijuana. *Med J Aust* **156**, 495-497 (1992).
819. Mitchelson, F. Pharmacological agents affecting emesis. A review (Part I). *Drugs* **43**, 295-315 (1992).
820. Campbell, M. & Bateman, D. N. Pharmacokinetic optimisation of antiemetic therapy. *Clin Pharmacokinet* **23**, 147-160 (1992).
821. Tchekmedyian, N. S., Halpert, C., Ashley, J. & Heber, D. Nutrition in advanced cancer: anorexia as an outcome variable and target of therapy. *JPEN J Parenter Enteral Nutr* **16**, 88S-92S (1992).
822. Zheng, Z. M., Specter, S. & Friedman, H. Inhibition by delta-9-tetrahydrocannabinol of tumor necrosis factor alpha production by mouse and human macrophages. *Int J Immunopharmacol* **14**, 1445-1452 (1992).
823. Bruera, E. Current pharmacological management of anorexia in cancer patients. *Oncology (Huntingt)* **6**, 125-30; discussion 132, 137 (1992).
824. Bruera, E. Clinical management of anorexia and cachexia in patients with advanced cancer. *Oncology* **49 Suppl 2**, 35-42 (1992).
825. Mackie, K. & Hille, B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. *Proc Natl Acad Sci U S A* **89**, 3825-3829 (1992).

826. Caulfield, M. P. & Brown, D. A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. *Br J Pharmacol* **106**, 231-232 (1992).
827. Wang, M., Richards, A. L., Friedman, H. & Djeu, J. Y. Selective inhibition of natural killer but not natural cytotoxic activity in a cloned cell line by delta-9-tetrahydrocannabinol. *J Leukoc Biol* **50**, 192-197 (1991).
828. Plasse, T. F. et al. Recent clinical experience with dronabinol. *Pharmacol Biochem Behav* **40**, 695-700 (1991).
829. Watzl, B., Scuderi, P. & Watson, R. R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. *Int J Immunopharmacol* **13**, 1091-1097 (1991).
830. Gorter, R. Management of anorexia-cachexia associated with cancer and HIV infection. *Oncology (Huntingt)* **5**, 13-17 (1991).
831. Watzl, B., Scuderi, P. & Watson, R. R. Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. *Adv Exp Med Biol* **288**, 63-70 (1991).
832. Cabral, G. A. & Vasquez, R. Effects of marijuana on macrophage function. *Adv Exp Med Biol* **288**, 93-105 (1991).
833. Lane, M. et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. *J Pain Symptom Manage* **6**, 352-359 (1991).
834. Turkanis, S. A., Karler, R. & Partlow, L. M. Differential effects of delta-9-tetrahydrocannabinol and its 11-hydroxy metabolite on sodium current in neuroblastoma cells. *Brain Res* **560**, 245-250 (1991).
835. Specter, S., Lancz, G., Westrich, G. & Friedman, H. Combined immunosuppressive activities of delta-9-tetrahydrocannabinol and murine retrovirus. *Adv Exp Med Biol* **288**, 135-141 (1991).
836. Burstein, S. Cannabinoid induced changes in eicosanoid synthesis by mouse peritoneal cells. *Adv Exp Med Biol* **288**, 107-112 (1991).
837. Rowley, J. T. & Rowley, P. T. Tetrahydrocannabinol inhibits adenylyl cyclase in human leukemia cells. *Life Sci* **46**, 217-222 (1990).
838. Tashkin, D. P. Pulmonary complications of smoked substance abuse. *West J Med* **152**, 525-530 (1990).
839. Johnson, B. A. Psychopharmacological effects of cannabis. *Br J Hosp Med* **43**, 114-6, 118 (1990).
840. Tortorice, P. V. & O'Connell, M. B. Management of chemotherapy-induced nausea and vomiting. *Pharmacotherapy* **10**, 129-145 (1990).
841. Lane, M., Smith, F. E., Sullivan, R. A. & Plasse, T. F. Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. *Am J Clin Oncol* **13**, 480-484 (1990).
842. Stewart, D. J. Cancer therapy, vomiting, and antiemetics. *Can J Physiol Pharmacol* **68**, 304-313 (1990).
843. Howlett, A. C., Scott, D. K. & Wilken, G. H. Regulation of adenylyl cyclase by cannabinoid drugs. Insights based on thermodynamic studies. *Biochem Pharmacol* **38**, 3297-3304 (1989).
844. Shook, J. E. & Burks, T. F. Psychoactive cannabinoids reduce gastrointestinal

- propulsion and motility in rodents. *J Pharmacol Exp Ther* **249**, 444-449 (1989).
845. Grunberg, S. M. Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens. *Blood Rev* **3**, 216-221 (1989).
846. Kawakami, Y. et al. Suppression by delta-9-tetrahydrocannabinol of interleukin 2-induced lymphocyte proliferation and lymphokine-activated killer cell activity. *Int J Immunopharmacol* **10**, 485-488 (1988).
847. Trissel, L. A. & Flora, K. P. Stability studies: five years later. *Am J Hosp Pharm* **45**, 1569-1571 (1988).
848. Dill, J. A. & Howlett, A. C. Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. *J Pharmacol Exp Ther* **244**, 1157-1163 (1988).
849. Nabilone and other antiemetics for cancer patients. *Med Lett Drugs Ther* **29**, 2-4 (1988).
850. McCabe, M. et al. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. *Invest New Drugs* **6**, 243-246 (1988).
851. Manzo, M. Dronabinol and nabilone ease cancer chemotherapy. *Nursing* **18**, 81 (1988).
852. Cunningham, D. et al. A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. *Eur J Cancer Clin Oncol* **24**, 685-689 (1988).
853. Howlett, A. C. Regulation of adenylate cyclase in a cultured neuronal cell line by marijuana constituents, metabolites of delta-9-tetrahydrocannabinol, and synthetic analogs having psychoactivity. *NIDA Res Monogr* **79**, 148-157 (1987).
854. Little, P. J., Kaplan, N. C. & Martin, B. R. Pharmacological profile of delta 9-THC carbamate. *Alcohol Drug Res* **7**, 517-523 (1987).
855. Triozzi, P. L. & Laszlo, J. Optimum management of nausea and vomiting in cancer chemotherapy. *Drugs* **34**, 136-149 (1987).
856. Chan, H. S., Correia, J. A. & MacLeod, S. M. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. *Pediatrics* **79**, 946-952 (1987).
857. Yahya, M. D. & Watson, R. R. Immunomodulation by morphine and marijuana. *Life Sci* **41**, 2503-2510 (1987).
858. Niiranen, A. & Mattson, K. Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. *Am J Clin Oncol* **10**, 325-329 (1987).
859. Hanasono, G. K., Sullivan, H. R., Gries, C. L., Jordan, W. H. & Emmerson, J. L. A species comparison of the toxicity of nabilone, a new synthetic cannabinoid. *Fundam Appl Toxicol* **9**, 185-197 (1987).
860. Roffman, R. A. Stress inoculation training in the control of THC toxicities. *Int J Addict* **21**, 883-896 (1986).
861. Pomeroy, M., Fennelly, J. J. & Towers, M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. *Cancer Chemother Pharmacol* **17**, 285-288 (1986).
862. Dalzell, A. M., Bartlett, H. & Lilleyman, J. S. Nabilone: an alternative antiemetic for cancer chemotherapy. *Arch Dis Child* **61**, 502-505 (1986).
863. Crawford, S. M. & Buckman, R. Nabilone and metoclopramide in the treatment of

- nausea and vomiting due to cisplatin: a double blind study. *Med Oncol Tumor Pharmacother* **3**, 39-42 (1986).
864. Murray, J. B. Marijuana's effects on human cognitive functions, psychomotor functions, and personality. *J Gen Psychol* **113**, 23-55 (1986).
865. Donald, P. J. Marijuana smoking--possible cause of head and neck carcinoma in young patients. *Otolaryngol Head Neck Surg* **94**, 517-521 (1986).
866. Specter, S. C. et al. Marijuana effects on immunity: suppression of human natural killer cell activity of delta-9-tetrahydrocannabinol. *Int J Immunopharmacol* **8**, 741-745 (1986).
867. Niederle, N., Schutte, J. & Schmidt, C. G. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. *Klin Wochenschr* **64**, 362-365 (1986).
868. Dodds, L. J. The control of cancer chemotherapy-induced nausea and vomiting. *J Clin Hosp Pharm* **10**, 143-166 (1985).
869. Ungerleider, J. T. et al. THC or Compazine for the cancer chemotherapy patient--the UCLA study. Part II: Patient drug preference. *Am J Clin Oncol* **8**, 142-147 (1985).
870. Synthetic marijuana for nausea and vomiting due to cancer chemotherapy. *Med Lett Drugs Ther* **27**, 97-98 (1985).
871. Ward, A. & Holmes, B. Nabilone. A preliminary review of its pharmacological properties and therapeutic use. *Drugs* **30**, 127-144 (1985).
872. Perlin, E. et al. Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. *J Pharm Sci* **74**, 171-174 (1985).
873. Landauer, M. R., Balster, R. L. & Harris, L. S. Attenuation of cyclophosphamide-induced taste aversions in mice by prochlorperazine, delta 9-tetrahydrocannabinol, nabilone and levonantradol. *Pharmacol Biochem Behav* **23**, 259-266 (1985).
874. Citron, M. L. et al. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. *Cancer Treat Rep* **69**, 109-112 (1985).
875. Niiranen, A. & Mattson, K. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. *Am J Clin Oncol* **8**, 336-340 (1985).
876. Hiller, E. & Gerhartz, H. [New aspects in the antiemetic therapy of cytostatic drug-induced vomiting]. *Klin Wochenschr* **62**, 441-445 (1984).
877. Dow, G. J., Meyers, F. H., Stanton, W. & Devine, M. L. Serious reactions to oral delta-9-tetrahydrocannabinol in cancer chemotherapy patients. *Clin Pharm* **3(1)**, 14 (1984).
878. Stoudemire, A., Cotanch, P. & Laszlo, J. Recent advances in the pharmacologic and behavioral management of chemotherapy-induced emesis. *Arch Intern Med* **144**, 1029-1033 (1984).
879. Fiore, J. J. & Gralla, R. J. Pharmacologic treatment of chemotherapy-induced nausea and vomiting. *Cancer Invest* **2**, 351-361 (1984).
880. Niamatali, C., Fallon, S. D. & Egan, E. L. Nabilone in the management of prochlorperazine resistant cancer chemotherapy induced emesis. *Ir Med J* **77**, 276-277 (1984).
881. listed], [N. A. Nabilone and high-dose metoclopramide: anti-emetics for cancer

- chemotherapy. *Drug Ther Bull* **22**, 9-11 (1984).
882. Frytak, S., Moertel, C. G. & Rubin, J. Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients. *Cancer Treat Rep* **68**, 1427-1431 (1984).
883. Kaplan, N. C. Dichloroethyl carbamoyl ester of delta-9-tetrahydrocannabinol. Chemical synthesis and biological testing and evaluation as a potentially site-specific anti-tumor agent. *Sci Sin [B]* **27**, 1048-1058 (1984).
884. Eyre, H. J. & Ward, J. H. Control of cancer chemotherapy-induced nausea and vomiting. *Cancer* **54**, 2642-2648 (1984).
885. Gralla, R. J. et al. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. *Cancer Treat Rep* **68**, 163-172 (1984).
886. Bakowski, M. T. Advances in anti-emetic therapy. *Cancer Treat Rev* **11**, 237-256 (1984).
887. George, M., Pejovic, M. H., Thuair, M., Kramar, A. & Wolff, J. P. [Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin]. *Biomed Pharmacother* **37**, 24-27 (1983).
888. Laszlo, J. Nausea and vomiting as major complications of cancer chemotherapy. *Drugs* **25 Suppl 1**, 1-7 (1983).
889. Carey, M. P., Burish, T. G. & Brenner, D. E. Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues. *Ann Intern Med* **99**, 106-114 (1983).
890. Treffert, D. A. & Joranson, D. E. delta 9-Tetrahydrocannabinol and therapeutic research legislation for cancer patients. *JAMA* **249**, 1469-1472 (1983).
891. Hogan, P., Sharpe, M., Smedley, H. & Sikora, K. Cannabinoids and hCG levels in patients with testicular cancer. *Lancet* **2(8359)**, 1144 (1983).
892. Ahmedzai, S., Carlyle, D. L., Calder, I. T. & Moran, F. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. *Br J Cancer* **48**, 657-663 (1983).
893. Heim, M. E. [Cannabis and cannabinoids. Possibilities of their therapeutic use]. *Fortschr Med* **100**, 343-346 (1982).
894. Cone, L. A., Greene, D. S. & Helm, N. A. Use of nabilone in the treatment of chemotherapy-induced vomiting in an outpatient setting. *Cancer Treat Rev* **9 Suppl B**, 63-70 (1982).
895. Laszlo, J. Treatment of nausea and vomiting caused by cancer chemotherapy. *Cancer Treat Rev* **9 Suppl B**, 3-9 (1982).
896. Stark, P. The pharmacologic profile of nabilone: a new antiemetic agent. *Cancer Treat Rev* **9 Suppl B**, 11-16 (1982).
897. Tetrahydrocannabinol (THC) for cancer patients. A review of the National Cancer Institute program in Wisconsin. *Wis Med J* **81**, 24 (1982).
898. Stark, P. Study design for the evaluation of the efficacy and safety of nabilone. *Cancer Treat Rev* **9 Suppl B**, 35-37 (1982).
899. Lemberger, L. et al. Pharmacokinetics, metabolism and drug-abuse potential of nabilone. *Cancer Treat Rev* **9 Suppl B**, 17-23 (1982).
900. Einhorn, L. Nabilone: an effective antiemetic agent in patients receiving cancer chemotherapy. *Cancer Treat Rev* **9 Suppl B**, 55-61 (1982).
901. Levitt, M. Nabilone vs. placebo in the treatment of chemotherapy-induced nausea

- and vomiting in cancer patients. *Cancer Treat Rev* **9 Suppl B**, 49-53 (1982).
902. Stark, P. Nabilone and cancer chemotherapy. *Ann Intern Med* **96(1)**, 122 (1982).
903. Joss, R. A. et al. Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy. *Cancer Chemother Pharmacol* **9**, 61-64 (1982).
904. Wada, J. K. et al. Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. *Cancer Treat Rev* **9 Suppl B**, 39-44 (1982).
905. Ungerleider, J. T. et al. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. *Cancer* **50**, 636-645 (1982).
906. Weddington, W. W. J., Miller, N. J. & Sweet, D. L. Anticipatory nausea and vomiting associated with cancer chemotherapy. *N Engl J Med* **307(13)**, 825-826 (1982).
907. Jones, S. E., Durant, J. R., Greco, F. A. & Robertone, A. A multi-institutional Phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting. *Cancer Treat Rev* **9 Suppl B**, 45-48 (1982).
908. Johansson, R., Kilkku, P. & Groenroos, M. A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. *Cancer Treat Rev* **9 Suppl B**, 25-33 (1982).
909. Dow, G. J. & Meyers, F. H. The California program for the investigational use of THC and marihuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapy. *J Clin Pharmacol* **21**, 128S-132S (1981).
910. Scigliano, J. A. THC therapeutic research by independent and state-sponsored investigators: a historical review. *J Clin Pharmacol* **21**, 113S-121S (1981).
911. Procedure for obtaining THC for cancer patients. *JAMA* **246**, 15-19 (1981).
912. Aapro, M. S. Prevention of chemotherapy-induced nausea and vomiting in patients with cancer. *Ariz Med* **38**, 843-845 (1981).
913. Levitt, M. et al. Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications. *J Clin Pharmacol* **21**, 103S-109S (1981).
914. Einhorn, L. H., Nagy, C., Furnas, B. & Williams, S. D. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. *J Clin Pharmacol* **21**, 64S-69S (1981).
915. Montour, J. L., Dutz, W. & Harris, L. S. Modification of radiation carcinogenesis by marihuana. *Cancer* **47**, 1279-1285 (1981).
916. Abraham, D., Pina, K. R. & Davignon, J. P. Mechanism for national distribution of delta 9-tetrahydrocannabinol (NSC-134454). *J Clin Pharmacol* **21**, 122S-127S (1981).
917. Gunby, P. Many cancer patients receiving THC as antiemetic. *JAMA* **245**, 1515, 1518 (1981).
918. Goldstein, M. S. & Williams, F. F. How we comply with federal guidelines on THC dispensing. *Pharm Times* **47**, 32-36 (1981).
919. Anderson, P. O. & McGuire, G. G. Delta-9-tetrahydrocannabinol as an antiemetic. *Am J Hosp Pharm* **38**, 639-646 (1981).
920. Poster, D. S., Penta, J. S., Bruno, S. & Macdonald, J. S. delta 9-tetrahydrocannabinol in clinical oncology. *JAMA* **245**, 2047-2051 (1981).

921. Sweet, D. L., Miller, N. J., Weddington, W., Senay, E. & Sushelsky, L. delta 9-Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study. *J Clin Pharmacol* **21**, 70S-75S (1981).
922. Penta, J. S., Poster, D. S., Bruno, S. & Macdonald, J. S. Clinical trials with antiemetic agents in cancer patients receiving chemotherapy. *J Clin Pharmacol* **21**, 11S-22S (1981).
923. Benowitz, N. L. & Jones, R. T. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. *J Clin Pharmacol* **21**, 214S-223S (1981).
924. Garb, S. Cannabinoids in the management of severe nausea and vomiting from cancer chemotherapy. Some additional considerations. *J Clin Pharmacol* **21**, 57S-59S (1981).
925. Chang, A. E. et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. *Cancer* **47**, 1746-1751 (1981).
926. Cocchetto, D. M., Cook, L. F. & Cato, A. E. A critical review of the safety and antiemetic efficacy of delta-9-tetrahydrocannabinol. *Drug Intell Clin Pharm* **15**, 867-875 (1981).
927. Colls, B. M., Ferry, D. G., Gray, A. J., Harvey, V. J. & McQueen, E. G. The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. *N Z Med J* **91**, 449-451 (1980).
928. Earhart, R. H. & Buchanan-Davidson, D. J. Tetrahydrocannabinol as an antiemetic for cancer patients. *Wis Med J* **79**, 47-48 (1980).
929. Winokur, S. H., Baker, J. J., Lokey, J. L. & Price, N. A. Marijuana for nausea and vomiting in cancer patients. *J Med Assoc Ga* **69**, 919-920 (1980).
930. Marijuana for nausea and vomiting due to cancer chemotherapy. *Med Lett Drugs Ther* **22**, 41-43 (1980).
931. Sallan, S. E. & Cronin, C. M. Is THC an effective antiemetic for cancer patients? Opinion 2. *CA Cancer J Clin* **30**, 283-285 (1980).
932. Frytak, S. Is THC an effective antiemetic for cancer patients? Opinion 1. *CA Cancer J Clin* **30**, 278-282 (1980).
933. Seipp, C. A., Chang, A. E., Shiling, D. J. & Rosenberg, S. A. In search of an effective antiemetic: a nursing staff participates in marijuana research. *Cancer Nurs* **3**, 271-276 (1980).
934. Levy, J. A. & Heppner, G. H. Immunosuppression by marijuana and its cannabinoid constituents. *J Immunopharmacol* **2**, 159-177 (1980).
935. Steele, N., Gralla, R. J., Braun, D. W. J. & Young, C. W. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. *Cancer Treat Rep* **64**, 219-224 (1980).
936. Lucas, V. S. J. & Laszlo, J. delta 9-Tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. *JAMA* **243**, 1241-1243 (1980).
937. Colls, B. M. Cannabis and cancer chemotherapy. *Lancet* **1**, 1187-1188 (1980).
938. Sallan, S. E., Cronin, C., Zelen, M. & Zinberg, N. E. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. *N Engl J Med* **302**, 135-138 (1980).

939. Williams, C. J., Bolton, A., de Pemberton, R. & Whitehouse, J. M. Antiemetics for patients treated with antitumor chemotherapy. *Cancer Clin Trials* **3**, 363-367 (1980).
940. London, S. W., McCarthy, L. E. & Borison, H. L. Suppression of cancer chemotherapy-induced vomiting in the cat by nabilone, a synthetic cannabinoid. *Proc Soc Exp Biol Med* **160**, 437-440 (1979).
941. Herman, T. S. et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. *N Engl J Med* **300**, 1295-1297 (1979).
942. Frytak, S. et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. *Ann Intern Med* **91**, 825-830 (1979).
943. Chang, A. E. et al. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. *Ann Intern Med* **91**, 819-824 (1979).
944. Bedell, S. E. Cannabis and cancer chemotherapy. *Ann Intern Med* **90(2)**, 276 (1979).
945. Gylys, J. A., Doran, K. M. & Buyniski, J. P. Antagonism of cisplatin induced emesis in the dog. *Res Commun Chem Pathol Pharmacol* **23**, 61-68 (1979).
946. Ekert, H., Waters, K. D., Jurk, I. H., Mabilia, J. & Loughnan, P. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. *Med J Aust* **2**, 657-659 (1979).
947. Mechoulam, R. & Carlini, E. A. Toward drugs derived from cannabis. *Naturwissenschaften* **65**, 174-179 (1978).
948. Toro-Goyco, E., Rodriguez, M. B. & Preston, A. M. On the action of delta 9-tetrahydrocannabinol as an inhibitor of sodium- and potassium-dependent adenosine triphosphatase. *Mol Pharmacol* **14**, 130-137 (1978).
949. Staquet, M., Gantt, C. & Machin, D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. *Clin Pharmacol Ther* **23**, 397-401 (1978).
950. Herman, T. S. et al. Nabilone: a potent antiemetic cannabinol with minimal euphoria. *Biomedicine* **27**, 331-334 (1977).
951. Warner, W., Harris, L. S. & Carchman, R. A. Inhibition of corticosteroidogenesis by delta-9-tetrahydrocannabinol. *Endocrinology* **101**, 1815-1820 (1977).
952. Friedman, M. A. In vivo effects of cannabinoids on macromolecular biosynthesis in Lewis lung carcinomas. *Cancer Biochem Biophys* **2**, 51-54 (1977).
953. Nichols, D. E., Mason, D. L. & Jacobsen, L. B. Allylbenzene analogs of delta-9-tetrahydrocannabinol as tumor growth inhibitors. *Life Sci* **21**, 1245-1248 (1977).
954. Carchman, R. A., Harris, L. S. & Munson, A. E. The inhibition of DNA synthesis by cannabinoids. *Cancer Res* **36**, 95-100 (1976).
955. White, A. C., Munson, J. A., Munson, A. E. & Carchman, R. A. Effects of delta-9-tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture. *J Natl Cancer Inst* **56**, 655-658 (1976).
956. Noyes, R. J., Brunk, S. F., Avery, D. A. & Canter, A. C. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. *Clin Pharmacol Ther* **18**, 84-89 (1975).
957. Patel, A. R. & Gori, G. B. Preparation and monitoring of marijuana smoke condensate samples. *Bull Narc* **27**, 47-54 (1975).
958. Munson, A. E., Harris, L. S., Friedman, M. A., Dewey, W. L. & Carchman, R. A. Antineoplastic activity of cannabinoids. *J Natl Cancer Inst* **55**, 597-602 (1975).
959. Sallan, S. E., Zinberg, N. E. & Frei, E. Antiemetic effect of delta-9-

tetrahydrocannabinol in patients receiving cancer chemotherapy. *N Engl J Med* **293**, 795-797 (1975).

960. Noyes, R. J., Brunk, S. F., Baram, D. A. & Canter, A. Analgesic effect of delta-9-tetrahydrocannabinol. *J Clin Pharmacol* **15**, 139-143 (1975).